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The release of porcine endogenous retrovirus (PERV) particles from pig cells is a potential 
risk factor during xenotransplantation by way of productively infecting the human transplant 
recipient. Potential countermeasures against PERV replication are restriction factors, such as 
SAMHD1, that block retroviral replication. SAMHD1 is a triphosphohydrolase that depletes 
the cellular pool of dNTPs in non-cycling cells preventing retroviral reverse transcription. 
Restriction factors and innate immune responses are the first line of defense against invading 
pathogens. Sensing of viruses in a cell usually results in the production of type I IFNs that 
lead to the activation of IFN-stimulated genes.  
The first part of this study focuses on the analysis of the antiviral activity of SAMHD1 against 
PERV-A/C in human immune cells. To study that, PERV-A/Cs originating from activated 
porcine PBMCs was used to infect human primary cells from healthy human donors. In 
parallel, primary cells were transduced with virus-like particles (VLPs) lacking or containing 
the Vpx protein from SIVmac239. The result showed that SAMHD1 potently restricts PERV-
A/C reverse transcription in human monocytes, monocyte-derived dendritic cells (MDDC), 
macrophages (MDM) or resting-CD4+ T-cells and in monocytic THP-1 cells. Degradation of 
SAMHD1 by SIVmac Vpx or CRISPR/Cas9 knock-out of SAMHD1 allowed for PERV 
reverse transcription. Addition of deoxynucleosides alleviated the SAMHD1-mediated 
restriction suggesting that SAMHD1-mediated degradation of dNTPs restricts PERV 
replication in these human immune cells. 
The aims in the second part of this study were to investigate the IFN response by monitoring 
induction of IFN stimulated genes following infection by PERV-A/Cs, and to identify the 
signaling pathways, which play a role in the type I IFNs response. The results showed that 
PERV-A/C increased (over 100-fold) CXCL-10 production in human MDDCs, monocytes 
and MDMs compared with non-infected cells or heat-inactivated virus. Treatment with 
VLP+Vpx or empty VLP did not cause more CXCL-10 induction compared with untreatment. 
The JAK-inhibitor (AT9283) reduced the CXCL-10 induction in infected cells indicating that 
the JAK/STAT pathway is activated by PERV-A/C infection of primary human myeloid cells.  
In conclusion, the findings in this work highlight SAMHD1 as a potential barrier to PERV-





Die Freisetzung von Porcinen Endogenen Retrovien (PERVs) aus Schweinezellen ist ein 
potenzieller Risikofaktor während der Xenotransplantation. PERV ist in der Lage, in humanen 
Zelllinien zu replizieren. Mögliche Abwehrmechanismen gegen die PERV-Replikation sind 
zelluläre Restriktionsfaktoren. Dazu gehört SAMHD1, eine Triphosphohydrolase, die den 
zellulären dNTP Pool in sich nicht teilenden Zellen erschöpft und die reverse Transkription 
damit verhindert. Restriktionsfaktoren und die angeborene Immunität sind die erste 
Verteidigungslinie gegen eindringende Krankheitserreger. Die Erkennung viraler Strukturen 
führt oftmals zur Produktion von Typ-I-Interferonen und nachfolgend zur Expression von 
IFN-stimulierten Genen.  
Der erste Teil dieser Arbeit fokussiert auf den Nachweis der antiviralen Aktivität von 
SAMHD1 gegen rekombinante PERV-A/C in menschlichen Immunzellen. Um dies zu 
untersuchen, wurden diese Viren aus aktivierten PBMCs von Schweinen gewonnen, um 
humane Primärzellen von gesunden Spendern zu infizieren. Parallel dazu wurden 
Primärzellen mit virusähnlichen Partikeln transduziert, welche zum Teil zusätzlich das Vpx-
Protein von SIVmac239 enthielten. Das Ergebnis zeigte, dass SAMHD1 die reverse 
Transkription von PERV-A/C in menschlichen Monozyten, von Monozyten abgeleiteten 
dendritischen Zellen (MDDC), Makrophagen (MDM) oder ruhenden CD4+ T-Zellen und in 
monozytischen THP-1-Zellen wirksam einschränkt. Die Degradation von SAMHD1 durch 
SIVmac Vpx oder CRISPR/Cas9-Knock-out von SAMHD1 ermöglichte die reverse 
Transkription von PERV. Die Zugabe von Deoxynukleosiden milderte die SAMHD1-
vermittelte Restriktion, was darauf hindeutet, dass der SAMHD1-vermittelte Abbau von 
dNTPs die PERV-Replikation in diesen menschlichen Immunzellen einschränkt. 
Im zweiten Teil dieser Studie erfolgte die Untersuchung der IFN-Reaktion durch Analyse der 
Induktion von IFN-stimulierten Genen in humanen Primärzellen nach Infektion durch PERV-
A/C. Die Ergebnisse zeigen, dass PERV-A/C die CXCL-10-Produktion in humanen MDDCs, 
Monozyten und MDMs über 100-fach erhöht. Aufgrund der profunden Inhibition dieser 
Aktivierung mit dem JAK-Inhibitor (AT9283) wird daraus geschlossen, dass dieser 
Signalweg für die CXCL-10 Induktion bei einer PERV-A/C Infektion in humanen 
myeloischen Zellen verantwortlich ist. Die erhaltenen Ergebnisse belegen dass SAMHD1 ein 
potenzielles Hindernis für die Übertragung von PERV-A/C von Schweinetransplantaten auf 




2.1      Retroviruses 
The Retroviridae are enveloped single-stranded (+) RNA viruses. Viral RNA is reverse 
transcribed by reverse transcriptase (RT) during the replication cycle and integrated as 
provirus into the genome of the host cell. 
More than 100 years ago, the two pathologists Vilhelm Ellermann and Oluf Bang succeeded 
in describing the first retroviruses, as cell-free filtrates triggered mouse and fowl leukemia [1]. 
In 1911, the american peyton rous discovered that ultra filtrates from sarcomas of the fowl led 
new tumors in healthy, susceptible fowls [2]. Later, the virus, responsible for these tumors 
was named as the Rous sarcoma virus (RSV). Mouse mammary tumor virus (MMTV)  was 
discovered by Bittner In the year 1936 as other retroviruses associated with tumor in the 
mammary glands of mice [3]. The importance find out was the identification of ribonucleic 
acid in RSV particles in 1961 by Crawford [4]. A few years later, the reverse transcriptase 
essential for retroviruses and their propagation strategy was discovered and described in 
parallel by Howard M. Temin and David Baltimore [5, 6]. The first human retrovirus, 
responsible for tumorigenesis in humans, was described by Gallo in 1980 and is known as the 
human T-cell leukemia virus (HTLV) [7]. Almost in parallel, Luc Montagnier succeeded in 
1983 in isolating Human Immunodeficiency Virus Type 1 (HIV-1) from blood samples of 
AIDS patients [8, 9]. 
With the discovery of complex retroviruses, the categorization of retroviruses by morphology 
was replaced with new criteria for defining the Retroviridae. The International Committee on 
Taxonomy of Viruses (ICTV) currently classifies retroviridae into two subfamilies: 
orthoretroviridae and the spuma retroviridae (Fig.2.1, [10]). A taxonomy based on the 
phylogenetic evolution (sequence relatedness of reverse transcriptase, analysis of virus 
morphology, its pathogenesis and host specificity) classified the orthoretroviridae in 7 genera: 
Alpharetroviruses, Betaretroviruses, Deltaretroviruses, Gammaretroviruses, Epsilon-
retroviruses and the Lentiviriuses while the Spumaviridae family comprises one genus the 
Foamiviruses (ICTV). The first three genera are considered simple retroviruses, while the rest 
are considered complex and harbor small accessory proteins encoded by alternatively spliced 




Figure 2. 1 Phylogenetic tree of retroviruses [10]. 
2.1.1   Endogenous retrovirus 
Retroviruses can be exogenous or endogenous (ERV), both consist of the general set of 
retroviral proteins necessary for replication and assembly, the exogenous retroviruses can be 
transmitted horizontally from host to host and the endogenous retrovirus proviral integrated 
into the germline of all vertebrates by old exogenous retroviruses infection and transmitted 
vertically from generation to generation [12] [13]. In 1977 Van Nie et al. described a 
previously unknown infection pathway using the mouse mammary tumor virus (MMTV) [14]. 
Not only can MMTV infect new cells as an infectious exogenous virus particle released by the 
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cell, but also as an endogenous component of the germline cell genome transmitted to the next 
generation.  Based on the infection of an oocyte, spermatocytes or their progenitor cells by the 
retrovirus and not a somatic cell as usual, every offspring that develops from the germline cell 
carries the provirus in every single body cell, at the same chromosomal position and is subject 
to the Mendelian heredity [15]. Endogenous retroviruses do not undergo a complete 
replication cycle, but instead remain within the host genome as a provirus. The epigenetic 
factors like DNA methylation and histone modifications can upregulate the transcription of 
the ERV, which may impair its ability to complete replication cycle inside the healthy host 
[16-18]. 
Human chromosomes integrated with numerous retroviral sequences that form part of the 
genome. In total, human endogenous retroviruses (HERVs) sequences account for ∼8% of 
human genome [19, 20]. There are about 100 HERV families have been defined for the 
human genome [20]. HERV-K also referred to as HML-2, is the youngest and the most 
biologically active human endogenous retrovirus (HERV) family [17, 21]. Various studies 
have shown that HERV-K (HML-2) proviruses are capable of producing viral proteins and 
even whole particles [22, 23]. HERV-K (HML-2) particles are observed in some motor 
neuron disease, infection and cancer, but their involvement in humans disease is still being 
investigated [24, 25]. In the other side, a wide range of beneficial functions was described for 
ERVs, for example the env-gene of HERVs encodes for the expression of syncytins 
(Syncytin-1 and -2, respectively HERV-W and HERV-FRD), which is essential for the 
formation of syncytiotrophoblast early during embryogenesis [26, 27]. In addition, Env 
proteins may be play role in immunosuppression to save the embryo in the beginning of 
pregnant [28].  
2-1.1.1 Porcine Endogenous Retroviruses (PERV) 
In 1970 was the first description of PERV particles in the supernatant of porcine kidney 
(PK15) cells and other porcine cells such as peripheral blood mononuclear cells (PBMCs) 
[29-31]. PERVs morphological and genomic characteristics belong to the genus 
gammaretrovirus; therefore they are closely related to MLV, feline leukemia virus (FeLV), 
gibbon ape leukemia virus (GaLV), and koala retrovirus (KoRV) [32-34] (Fig, 2.2). 
It was considered  that PERVs probably originated from murine retroviruses [35]. The 
analysis of the mutations in the long terminal repeats (LTRs) of the PERV sequences revealed 
that the endogenization may have occurred before 7.6 million years [36, 37]. PERVs are 
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present in the genomes of all pigs and the copy number of PERVs in the porcine genome 
didn’t stop to increase due to re-infection and intracellular transposition [38-40]. Some of 
PERVs are able to infect human cells in vitro, for that PERV may represent a special risk for 
xenotransplantation [41, 42]. The replication-competent PERVs are further classified in three 
subtypes according to their env sequence; PERV-A, -B and –C (Fig.2.3) [43, 44]. PERV-A 
and PERV-B are present in the genomes of all pig strains, at different copy numbers and can 
infect not only pig cells but also cells of other species like human [45-47]. On the other hand, 
PERV-C is integrated into the genome in many, but not all pigs and is able to infect only pig 
cells [48]. 
 
Figure 2. 2 PERVs produced by infected human cells as shown by transmission (A) and scanning 
(B) electron microscopy. (Klaus Boller, Paul Ehrlich Institute, Langen, Germany.) 
A recombination between PERV-A and -C is possible and results in a highly replicating form 
named PERV-A/-C, which can also infect human primary cells in vitro [49]. This increase 
was associated with some substitutions in the variable region and increase in the length of 
LTR in the PERV-A/C [50].  
 
Figure 2. 3 The type of PERVs. 
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2.1.1.2 Structure of PERV 
PERV structures like other retroviruses, the viral particles have a diameter of about 100 nm 
(Fig.2.4). The outer cellular lipid double membrane of  PERV are envelope proteins, which 
contains the transmembrane glycoprotein (TM), bound to the surface glycoprotein (SU), and 
are visible in the EM as so called spikes  [51-53]. The matrix proteins (MA) are located inside 
the membrane which are connected to the membrane by myristic acid residues and form a net-
like protein layer. Inside the virus a virus capsid protein, which protect a complex of 
nucleocapsid proteins (NC) and two single-stranded RNA bound to several copies of reverse 
transcriptase (RT), protease (PR) and integrase (IN), which form together the inner core [51]. 
 
Figure 2. 4 PERV structure (modified from BioRender). 
2.1.1.3 Genomic organization and function 
The genomic RNA of PERV consists of two identical single strands with positive polarity of 
about 8100 base pairs and includes both coding and non-coding sequences [41].The non-
coding sequences LTR (Long Terminal Repeat) are localized at both ends of the RNA which 
includes the R (redundant), U5 (unique) regions at the 5′-end and the U3 and R regions at the 
3′-end. A primer-binding site (PBS) is located at the end of the U5 element and is important 
for initiating reverse transcription by annealing to a cellular tRNA Gly [54]. Both LTRs are 
important for the viral integration and transcription and contain cis-active sequences, 
promotors and enhancers [55, 56]. Between non-coding  sequences,  there  are  sequences  
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encoding  the  Gag,  Pol, and  Env  proteins,  that  is,  the gag (group-specific  antigen), pol 
(polymerase  gene),  and env (envelope  gene)  genes, respectively (Fig.2.5). The gag gene 
encodes the structural proteins of the matrix (MA), capsid (CA), and nucleocapsids (NC). CA  
is  the  main  structural  protein of  PERV, with  a  molecular  weight  of  about  27  kDa.  NC 
protein has a molecular weight of about 10 kDa (p10),  and  it  is  responsible  for  the  
efficient  packaging  of  RNA in the virion [51, 57, 58]. Gammaretroviruses have an 
additional p12 protein localized in the Gag polyprotein between MA and CA, which play role 
in the integration of the dsDNA within the genome of the host cell and in the release of new 
virus particles [59, 60] .  
 
Figure 2. 5 Genome structures of the proviral PERV. LTR; long terminal repeat, Gag; group-
specific antigen gene, Pro/Pol; protease/polymerase gene, Env; envelope protein gene. Env subtypes 
of PERVs and the A/C recombinant are presented. 
Protease (PR), reverse transcriptase (RT), and integrase (IN) are encoded by the pol gene. PR 
is a protein with a molecular weight of 14 kDa (p14) that catalyzes the proteolysis of the Gag 
and Pol polyproteins into the proteins described above [41, 61]. RT is essential for the 
transcription of viral ssRNA into dsDNA and IN helps the dsDNA to integrate into the host 
genome [58].   
The Env spikes on the surface of the virion are important for viral attachment and the fusion 
of viral and cell membranes during the infection process. The env gene encodes the precursor 
proteins of the env as a single polyprotein, which is cleaved by a cellular furin-like protease 
into two components: the surface envelope protein SU (gp70) and the transmembrane 
envelope protein TM (p15E) [42, 61]. The  env  protein  is  produced only  from  spliced env 
mRNA  [62].  The glycosylation of the env protein is necessary for virus infectivity by 
influencing the binding to the host receptor; env glycoprotein contains different glycosylation 
sites: about 10 in PERV-A, 6 in PERV- B, and 8 in PERV-C [52, 63]. The SU protein has the 
receptor-binding domain (RBD) on the N-terminus; therefore it is the responsible for binding 
to the host receptor [64, 65]. TM protein doesn’t present sequence variations likes SU protein 
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and the main role of TM protein is to mediate the membrane fusion reaction during infection 
[66]. 
Between the U5 region and gag, the primer-binding   site   (PBS) is located, which is 
responsible for starting the first DNA strand-reverse transcription (RT). This sequence is 
complementary with glycine-tRNA in the case of PERV-A and PERV-B, but with proline-
tRNA for PERV-C [67]. The genome contains also the splice donor and acceptor sites which 
result in two splice variants. The first variant sequence coding for Gag and Pol proteins, and 
the second coding for Env protein [68]. The polypurine tract (PPT) plays role in synthesis the 
second strand of the DNA copy, PPT  is located at the end env region [60].  The 5´-end of the 
viral genome consists of a cap unit and the 3´-end contains a polyA tail [41, 51, 68]  
2.1.1.4 PERV Replication 
The replication cycle of PERVs can be divided into early and late phases similar to 
gammaretroviruses such as MLV. The early phase includes binding to a specific receptor on 
the cell surface, entry into the cell, reverse transcription, and cDNA integration within the 
genome of the host cell (Fig.2.6). The late phase includes the expression of retrovirus RNA 
genes, virus protein particles and releases the maturation virus. 
The Early Phase: The viral cycle infection begins with the binding of PERV SU to the 
suitable receptor on the host cell. Until now, only receptor for PERV-A has been identified. In 
pigs, it is porcine PERV-A receptor (PoPAR) [69].  Two receptors in human cells were 
described and named the human PERV-A Receptor (HuPAR1 and HuPAR2), also known as 
G-protein-coupled receptors 172A and 172B [70]. More recently, these receptors have been 
renamed as SLC52A2 and SLC52A1, respectively [71]. SLC52A1, 2 receptors contain 11 
transmembrane domains and thus a transporter function can be recognized and are encoded by 
genes located on chromosomes 8 and 17, respectively, which are found in most of the human 
tissues [69, 72]. The PERV-B receptor(s) are still unknown. 
The binding of SU envelope protein with its cell surface receptor activates the transmembrane 
protein (TM) and induces conformational changes in the gp70 protein. As a consequence, the 
viral Env fuses with the host cell membrane, and the genetic material of the retrovirus covered 
by the CA enters into the cytoplasm, where it undergoes partial disassembly, the viral 
nucleoprotein complex is liberated and the RNA genome is reverse transcribed into a double-
stranded DNA by the viral RT using cellular dNTPs [73, 74]. The double-stranded linear 
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DNA intermediate as well as the reverse transcriptase, matrix proteins and integrase are 
assembled together to form a subviral particle termed as pre-integration complex. PERV can 
integrate only the dividing cells, therefore PERV cDNA transfer from cytoplasm into the 
nucleus during mitosis, when the nuclear membrane has broken down.  
 
Figure 2. 6 The PERV replication cycle (modified from BioRender). 
 
The Late Phase: After nuclear import the viral DNA becomes integrated into the cell 
chromosome, the provirus DNA is transcribed by the host machinery to produce descendent 
retroviruses. The originated mRNA can be used for the production of viral proteins, or 
become the genomic RNA of new viral particles. Several cellular factors are involved in 
transcription by the cellular RNA polymerase II. The transcription of the provirus generates 
spliced and unspliced mRNAs and transported into the cytoplasm. Gag-polyproteins are 
transported to the cell membrane or aggregate directly at the cell membrane. Env-precursor 
proteins are synthesized at the membrane of the cytoplasmic reticulum and transported to the 
cell membrane [75]. The Ψ-signal in unspliced mRNA leads to packaging of viral RNA into 
virus particles [67]. These capsids are released from the cell by budding of the plasma 
membrane, which has incorporated also the viral envelope proteins. Budding of viruses is 
followed by cleavage of the precursor polyproteins by the viral and cellular proteases. 
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2.2  Xenotransplantation  
The definition of xenotransplantation is the transfer of living cells, tissues or organs between 
different species. Xenotransplantation includes also perfusion of foreign cells by blood of the 
host or acellular biomaterials (heart valves, blood vessels, tendons) of non-human species 
[76]. 
The aim of the xenotransplantation is to overcome the shortage of human donor material for 
transplantation, because the number of individuals waiting for an allotransplant is always 
increasing and many patients die before they get any organ. The history of 
xenotransplantation started in 1964, the chimpanzee kidney has been transplanted into a 
human with end-stage renal disease, the patient’s life was extended for nine months [77]. In 
1992 and 1996 two patients received a pig heart in Poland and India as well as the 
transplantation of two baboons and one pig livers in patients with liver failure [78-80]. 
Nevertheless, these trials showed limited success.  
The major problem of xenotransplantation is the rejection of cells, tissues, and organs; the 
transplanted material is usually rejected more rapidly and more violently than in the case with 
allogeneic transplants. The most reason for rejection is the anatomic-physiological 
incompatibility, which causes immune rejection of the xenografts, due to the phylogenetic 
distance between humans and animals [81]. Viral and bacterial infections can also transmitted 
with xenotransplantation and lead to functional loss of the transplant and death of the 
recipient [82]. In contrast to the transplantation of whole organs, the use of cells and tissues of 
porcine showed more promising and successful. In the last years, implantations of pig 
embryonic cells are used in the treatment of Parkinson´s disease, and pig liver cells are 
transplanted into human patients with liver failure [83]. The most successful 
xenotransplantation was the transplantation of porcine islet-cells in treating type I-diabetes 
[84].  
2.2.1 Pigs are ideal donors for xenotransplantation  
Pigs (Sus scrofa) are chosen for several reasons as suitable donor species for 
xenotransplantation in humans. The physiological and anatomical properties of pigs’ organs 
are similar to human and come in different sizes [85, 86]. Pigs also have a short gestation time 
about 115 days, reach the reproductive maturity period in 4-8 months, produce high number 
of large sized litters by multiple births (5-12) and most of their organs reach the maximum 
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size suitable for human body within only 6 months [87]. Other advantages using pigs as donor 
animals for xenotransplantation are their suitability for genetic engineering and this was 
shown by several studies which succeeded to generate pig clones from genetically modified 
porcine cells, for example, human complement regulating genes or by the knockout of pig cell 
surface molecules [88]. Moreover, pigs can be easily bred in hygienic environments under 
control with low costs and the  risk of zoonotic transmission  is much  lower than  primates 
due  to  their greater phylogenetic  distance from humans [89]. Because millions of pigs are 
slaughtered annually for human consumption the ethical concerns are less restricted and the 
idea of use of pigs for transplantation is more accepted in the public [90].  
To use porcine organs for xenotransplantation, there are several difficulties and barriers 
remain such as the physiological incompatibilities, the immunological concerns and the major 
problem is also the infectious risk for human patients by different viruses. More than 20 
potentially lethal viruses are known that could be transmitted from animals to humans 
including hepatitis A and B, Marburg virus, Ebola, herpes B, simian virus 40 (SV40) and 
simian immunodeficiency virus (SIV), whereas the human immunodeficiency virus (HIV) 
type -1 and -2 are a result of cross species transmission between the SIV of chimpanzee 
(SIVcpz) and the sooty mangabey (SIVsm) [91-94]. Human herpes virus 8 (HHV-8), which 
transmitted from monkey can kill  humans in a matter of short time [95].  
2.2.2 PERV and xenotransplantation risk 
PERVs are widely distributed and integrated within the genome of all pigs. They are present 
in various proportions depending on the pig breed, tissue type, and retrovirus subtype [39, 47, 
96]. There are three replication‐ competent subtypes of PERVs: PERV‐ A, and B, replicate in 
human cells in vitro but PERV-C infects only porcine cells [45]. Recently, recombinants 
PERV-A/Cs were discovered in different organs and tissues of pigs but not in the germline.  
The risk of PERV transmission to various human cells, including peripheral blood 
mononuclear cells (PBMCs) embryonic kidney cell (HEK-293) line, and normal dermal 
human fibroblasts (NHDFs) has been confirmed in vitro [97, 98]. Therefore PERVs ability to 
infection increases the concern, especially in the context of the eventual use of porcine cells, 
tissues, and organs in xenotransplantation. 
Until now, it has not been reported, that PERV can transmit in vivo among patients with type 
1 diabetes, after pancreatic islets xenografts [99, 100], recipients of pig’s nerve cells [83], 
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porcine skin graft recipients [101], and butchers exposed to contact with pig tissues. It is 
possible, that immunological response and restriction factors inhibit PERV activity in vivo 
and in the case of in vitro studies, we are not able to reproduce the complicated dependence 
networks that have a significant impact on the defense of cells against PERV infection in 
vivo.   
To reduce the risk of PERV transmission during human xenotransplantation, donor pigs 
should be selected depend on the absence of PERV-C to avoid the recombination between 
PERV-A and PERV-C to produce the high infectivity PERV-A/C. The expression of PERV in 
organs and Pig strains is different, for that the lowest expression of PERV-A and –B better 
used for xenotransplantation [96, 102]. For screening biological materials such as animal 
saliva or blood should be used to determine the PERV expression. However, if the number of 
PERV copies in the organ for xenotransplantation differs compared to the material used for 
screening, an investigation of the whole animal or of its sisters or brothers should be 
performed [103]. Detailed knowledge of the structure and replication cycle of PERVs is a 
requirement for planning strategies for PERV detection [104-106]. Such detection should be 
achieved at the genomic and proteomic levels using methods with adequate sensitivity and 
specificity. Polymerase chain reaction (PCR), with the use of the primers complementary to 
the conserved regions of the gag and pol genes, permits the detection of PERV proviruses in 
the analyzed biological material like PBMC or saliva, it was reported that PERV has high 
expression in PBMC. The virus subtype (PERV-A, - B, or -C) can be detected by the primers 
complementary to env gene. Concomitantly the potential risk of recombination between the 
subtypes can be determined (PERV-A/C). Primers complementary to the LTRs can serve for 
the amplification of the whole genome of PERV provirus [107, 108]. In addition, the 
detection of RT activity can give more confirms for the presence of the virus. Along with the 
increase of the number of copies of PERV RNA, RT activity can serve as a marker of the 
active replication cycle. The serology methods; western blot, ELISA, and 
immunofluorescence can be used to complements the diagnostics and confirm PERV 
infection [104, 105]. Viral particles can be visualization by transmission and scanning 
electron microscopy methods to confirm the presence of and their release from infected cells 
[32]. The genetic material of the virus can also be determined with the use of the in situ 
hybridization technique. This method allows finding the location of the viral nucleic acid and 
the percentage of infected cells, giving the chance to estimate the viral replication ability and 
the degree of integration in the host’s DNA [109]. 
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There are other viruses can transmissions during xenotransplantation. Hepatitis E virus (HEV) 
genotypes 3 and 4 can be detected in humans and animals, like pigs and the virus can be 
transmitted zoonotically by eating uncooked or undercooked pork products or meat [110]. 
Therefore HEV-GT3 and GT4 might pose a risk in xenotransplantation using pig cells, tissues 
or organs [111]. The other risk can associated with xenograft these porcine viruses, Porcine 
cytomegalovirus (PCMV), Porcine lymphotropic herpes viruses and Porcine circoviruses 
[112-116]. 
The risk of viral infections due to the use of pigs as donors in xenotransplantation is assessed 
to be lower than in the case of human allografts. The use of human donors also carries the risk 
of transmission of viral infections, such as cytomegalovirus (CMV), viral hepatitis B (HBV), 
C (HCV), E (HEV), Epstein–Barr virus (EBV) or human immunodeficiency virus (HIV) 
[117-119]. In allotransplantation may prevent complex diagnostics in the search for all 
possible human pathogens. The immunosuppression can also deplete the immunological 
barriers of the recipient. In the case of xenotransplantation, pigs devoid of pathogens should 
be bred to ensure the safety of the procedure. 
2.3  Restriction factors 
During their replication cycle in human cells, retroviruses interact with multiple replication 
barriers. As a first-line defense, host restriction factors can limit viral replication, which 
potently block retroviruses replication by intervening with various replication steps [120-122]. 
The  restriction factors characteristics are: (1) They have the ability to cause a significant 
decrease in viral infectivity, (2) they are counteracted by some viral accessory proteins, (3) 
they show signs of rapid evolution, and (4) their expression can be strongly induced by 
interferons (IFNs), thereby tightly linking their activity with the host’s immune system [123]. 
Complex retroviruses such as HIV and SIV evolved to circumvent these restriction factors 
allowing infection of human or monkey dividing cells, respectively. Both viruses either 
encode for accessory proteins that inactivate restriction factors during the replication cycle or 
carry mutations in those viral genes that encode targets for these restriction factors to avoid 
recognition [124]. In the last years, several restriction factor proteins with anti-HIV activity 
have been identified. Interestingly, many of them not only inhibit the replication of exogenous 
viruses like HIV-1, but were also found to restrict endogenous retroviruses and transposable 
elements. These factors include apolipoprotein B mRNA-editing enzyme catalytic 
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polypeptide-like 3 (APOBEC3) family members, Tetherin, Mx2, sterile alpha motif domain 
and HD domain containing protein 1 (SAMHD1), TRIM5alpha, and others [125-127]. 
APOBEC3G (A3G) is a single-stranded DNA cytidine deaminase that inactivates the coding 
capacity of viruses by deamination reactions that convert cytosine to uracil (C to U) during 
reverse transcription of the genomic HIV-1 RNA leads to G to A hyper-mutations in the 
newly synthesized in the minus-strand DNA [128, 129]. Human APOBEC3 (A3) proteins 
include hA3A, hA3B, hA3C, hA3DE, hA3F, hA3G, and hA3H [130]. The hA3F and hA3G 
are consider the main inhibitors of human immunodeficiency virus (HIV- 1) replication [131, 
132], hA3G has the ability to  inhibit the replication of other retroviruses, such as simian 
immunodeficiency virus (SIV), human T-cell lymphotropic virus (HTLV), murine leukemia 
virus (MLV), and retrotransposons [133, 134].  In several studies, they found that human 
APOBEC3G (A3G) blocks porcine endogenous retrovirus (PERV) replication by C-to-U 
deamination porcine endogenous retrovirus and inhibition of DNA strand transfer during 
PERV reverse transcription [135]. In addition, porcine A3 gene (A3Z2-Z3) can also inhibit 
PERV replication in a pseudotype assay as well as in a virus-spreading assay [136]. 
Another restriction factor is tetherin, also known as BST-2, which is an IFN-inducible 
membrane protein that efficiently blocks release of virion by directly tethering them to the 
cell surface and prevent the release of virus particles from the virus-producing cells. The 
antiretroviral activity of Tetherin is counteracted by the accessory protein Vpu of HIV-1 
[137]. It has been reported that human and porcine tetherin can inhibit PERV release from 
producer cells [138]. However, tetherin proteins from different species have different 
sensitivities to various viral countermeasures [139]. They showed also that a combination of 
tetherin and APOBEC3 was more efficient in PERV restriction than each individual 
restriction factor  [140].  
2.3.1     The restriction factor SAMHD1 
Sterile alpha motif domain and HD domain containing protein 1 (SAMHD1) is  an  IFN 
inducible  host  protein  acts as a deoxynucleoside triphosphate triphosphohydrolase 
(dNTPase) that depletes the intracellular pool of dNTPs, which is required for cellular DNA 
polymerase, by converting dNTPs into the corresponding nucleosides (dNs) and inorganic 
triphosphate, when dGTP binds to the allosteric binding site in SAMHD1 [141-143]. The 
discovery of SAMHD1 as a host restriction factor explains the importance of metabolic 
regulation as an additional mechanism to limit the replication of viral pathogens [144]. 
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SAMHD1 is constituently expressed at various levels in all cell types and highly expressed in 
myeloid lineage and resting CD4+T-cells [144, 145]. In non-cycling cells, such as 
macrophages, dendritic cells and resting CD4+ T-cells SAMHD1 is capable to restrict human 
and non-human retroviral infection by reducing the intracellular dNTP pool below the 
threshold that is necessary for complete reverse transcription to produce viral cDNA [141, 
146]. SAMHD1 is considered an important restriction factor for HIV-1 by preventing virus 
replication at reverse transcription by degrading the dNTP pool and inhibiting early steps of 
virus replication cycle, blockade at this step prevents the synthesis of full-length double-
strand DNA and disrupts later stages of the viral life cycle, including nuclear translocation 
and integration of proviral DNA [147, 148]. In addition, SAMHD1 can restrict other human 
viruses like DNA viruses that rely on dNTPs to replicate their genome such as herpes simplex 
virus 1 (HSV-1) and vaccinia virus [149, 150].  
2.3.1.1     Structure of SAMHD1 
Human SAMHD1 comprises 626 amino acids and contains two important domains (Fig.2.7 ): 
the sterile alpha motif (SAM) domain, which functions in protein–protein interactions and 
contributes to SAMHD1 nucleic acid binding, although it is not necessary for its nuclease 
activity in restriction [151]; the HD domain of SAMHD1 contains the enzymatic sites, which 
is essential for its triphosphohydrolase activity to hydrolysis the intracellular pool of dNTPs , 
RNA binding and nuclease activity, for that the expression of HD domain alone is enough to 
restrict HIV-1 and other retroviruses replication [141, 152]. At the N-terminus of SAMHD1 is 
the nuclear localization signal, therefore the predominant location of SAMHD1 is in the 
nucleus [153, 154], but a fraction of SAMHD1 is also found in the cytoplasm [147] . It was 
reported that SAMHD1 may also contain other nuclear localization signals since deletions of 
the N-terminal region did not lead to limit cytoplasmic expression of SAMHD1 [155], and 
SAMHD1 can relocalize in the cytosol if nuclear localization signal mutated [156]. It has 
been found that, the mutated versions of SAMHD1 that localized in the cytoplasm were still 
capable of restricting HIV-1 infection [154, 157]. SAMHD1 also contains a domain at the C-
terminus, which is the target domain for HIV-2/SIVsm Vpx accessory protein [158, 159]. 
Prior to the detected of the antiretroviral activity of SAMHD1, it was unclear how Vpx 
promotes the HIV-2 infection in non-cycling myeloid cells such as monocytes, macrophages 
and dendritic cells [160-162]. It is now confirm that Vpx counteracts SAMHD1 functions in 




Figure 2. 7 The structure and function of SAMHD1. (Top) Representative schematic of the 
important domains of SAMHD1, including enzymatic sites, nuclear localization signals and 
activation/phosphorylation site. (Bottom) How SAMHD1 restricts retroviruses by dNTP depletion 
[163]. 
To induce SAMHD1 degradation Vpx should interact with SAMHD1 physically in the 
nucleus [154, 155]. Vpx interacts with the cullin-4-based E3 ubiquitin ligase CRL4/DCAF1 
and recruits SAMHD1 to the Cul4/ CRL4/ DCAF1 complex by binding with the C-terminal 
domain of SAMHD1, leading to ubiquitination proteasomal degradation and relieving the 
antiviral activity of SAMHD1 to restricting retroviruses [157, 161, 164]. Following SAMHD1 
degradation by Vpx, the level of intracellular dNTP increased and the viral RNA reverse 
transcribed into cDNA and complete its replication cycle (Fig.2.8). The nuclear Vpx cannot 
degrade SAMHD1 mutants in the cytoplasm; also the mutant of Vpx that does not localize in 
the nucleus cannot deplete wild-type SAMHD1, which confirms the Vpx-SAMHD1 reactions 
occur in the nucleus [154, 165, 166]. In SIVsm and SIVmac, Vpx is packaged through an 
interaction with amino motifs in the carboxy-terminal p6 region of the Gag precursor 
polypeptide [167, 168]. Transfer of the P6gag motif of SIV SIVmac to the corresponding 
location of HIV-1 Gag results in HIV-1 that packages Vpx, which can infect non-dividing 
cells [168]. Virus-like particles (VLPs) can also deliver Vpx to myeloid cells [144] (Fig.2.8). 
In addition the C-terminus contains the phosphorylation residue T592; the Phosphorylation of 




Figure 2. 8 Vpx degrades SAMHD1 and increases the level of dNTP to reverse transcription. 
2.3.1.2 Regulation of SAMHD1 activity 
SAMHD1 has a crystal structure and the enzymatically active of SAMHD1 forms tetramers. 
It has been reported that SAMHD1 oligomerizes in a dGTP-dependent manner up to a 
tetramer and that the tetramerization of SAMHD1 is essential for its dNTPase and antiviral 
activities, whereas the inactive apo-form interconverts between monomer and dimer [140, 
169,170]. There are four allosteric nucleotide binding sites in the active tetramer, each 
capable of taking two dGTPs that serve to interconnect SAMHD1 chains into the tetrameric 
state [171]. Several biochemical and structural studies indicate that GTP also acts as allosteric 
cofactor enhancing the oligomerization. The cofactor-induced tetramerization has been 
reported to be critical for the role of dNTPase activity and the reverse transcriptase restriction 
of retroviral infection [172, 173]. The introduced mutation to the allosteric dGTP-binding site 
D137 does not undergo oligomerization and was mostly monomeric in the presence of 
dGTP22. The mutation of D137 (SAMHD1D137N) eliminates SAMHD1 dNTPase but not 
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RNase activity.  Unlike the dNTPase activity, the tetramerization of SAMHD1 is not required 
for its RNase activity [174]. 
2.3.1.3 SAMHD1 expressed in dividing and non-dividing cells, but the 
restriction activity of SAMHD1 in both cells types is different 
The antiviral activity function of SAMHD1 and its restriction capacity are not exclusively 
associated with its expression level; but instead are regulated by phosphorylation in cycling 
cells [145, 169]. SAMHD1 is phosphorylated at numerous residues, but the phosphorylation 
of threonine 592 was identified as necessary for the negative regulation of its anti-viral 
restriction activity [144, 169]. Cyclin-dependent kinase 1 (CDK1) and CDK2 in complex with 
cell cycle regulatory protein cyclin-A, phosphorylate SAMHD1 at T592 in the S-phase during 
cell cycle [170, 171]. CDK1 and cyclin-A are highly expressed in dividing cells. The amount 
of SAMHD1 protein may be different during various stages of the cell cycle depending on 
cell type. It was demonstrated that the highest levels of SAMHD1 happened during 
quiescence, while SAMHD1 expression was lower in dividing cells [172]. Several studies 
established that no up-regulated of the expression of human SAMHD1 protein by adding extra 
IFN-α or IFN-γ into human dendritic cells, macrophages and CD4+ T-cells [145, 153, 173]. 
On the other hand the expression can be induced in certain cell lines, such as U87-MG, HEK 
293T or HeLa cells [148]. It has been indicated in one study that IFN-α can induce SAMHD1 
expression in primary monocytes, but in another study did not demonstrate any increase [169, 
174].  
In monocyte-derived macrophages (MDM) SAMHD1 expression is increased by a 
combination of IL-12 and IL-18 that lead to cells with more resistant to HIV-1 infection 
[175]. The mechanism for increase SAMHD1 expression in some cell types by these 
cytokines is unknown. In recent study it was shown that type I and type II interferons increase 
activation of SAMHD1 via dephosphorylation at threonine-592 and  downregulated Cyclin-
dependent kinase 1 (CDK1) at the protein level  [176]. In addition SAMHD1 play essential 
role in the regulation of the cell cycle by preventing accumulation of G1 cells and arrest of the 
cell cycle [172] 
2-3-1-4 The Role of SAMHD1 in the Autoimmune Disorder 
SAMHD1 plays a central role in the immunity and nucleotide metabolism therefore the 
mutations to SAMHD1 can causes immune disease. Different SAMHD1 mutations have been 
found in several diseases [177, 178]. One of these autoimmune diseases is Aicardi-Goutières 
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Syndrome (AGS), which is associated with mutations in the enzyme activity site of SAMHD1 
[179, 180]. AGS is an autosomal genetic disorder characterized by encephalopathy, 
leukodystrophy, calcifications of the basal ganglia, psychomotor retardation, cerebrospinal 
fluid lymphocytosis and in around 40% of the AGS cases, death in the early childhood [181, 
182]. The mutation in some proteins, which involved in the nucleic acid metabolism like 
SAMHD1, TREX1, RNase H2, ADAR1, and MDA5, can cause accumulation in the 
intracellular dNTP and the endogenous nucleic acid debris that lead to immune sensing and an 
over-production of type one IFN [183]. Nearly 13% of all documented cases of AGS genetic 
disease were counted with the mutations in SAMHD1 [177]. LINE‐ 1 is the non‐ long 
terminal repeat retrotransposon, which comprises ~17% of the human genome. SAMHD1 can 
inhibit ORF2p‐ mediated LINE-1 reverse transcription by deplete the ORF2p level and 
enhancing stress granule formation [184]. Recently it has been reported that LINE‐ 1 is the 
potential trigger of systemic autoimmune disease [185]. LINE-1 nucleic acids were 
accumulated in cells with SAMHD1 mutation, which lose its inhibitory effect on LINE-1 
retrotransposition, that lead to nucleic acid sensing by cGAS and IFN signaling activating 
causing autoimmune AGS. In addition, SAMHD1-deficient monocytes, which are isolated 
from AGS patients with homozygous SAMHD1 mutations more susceptible for infection by 
HIV-1 [174], proposing a link between SAMHD1 function in both autoimmunity and HIV-1 
restriction. 
The mutation of SAMHD1 associated with AGS has several novel features not detected in 
other AGS associated genotypes, including cerebral vascular hemostasis, arthropathy, and 
mitochondrial DNA deletions [186]. The clinical presentation of SAMHD1 induced AGS may 
therefore provide evidence to the mechanism through which SAMHD1 functions in 
nucleotide homeostasis and negatively regulates innate immunity [187]. It has been reported 
that interferon levels in SAMHD1 knockout mice are increased, but do not developed to 
autoimmune disorder [188]. On other hand zebra fish showed similar interferon 
overexpression and cerebrovascular pathologies associated with SAMHD1 deletion, like the 
symptoms observed in AGS patients [189]. 
2.4    Innate Immune responses to viral infection 
Innate immune responses consider the first line of defense against invading pathogens. They 
are induced by activated pattern recognition receptors (PRRs) that recognize pathogen-
associated molecular patterns (PAMPs) [190]. Identification and characterization of the 
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molecular basis of DNA sensing represents a very important strategy employed by the innate 
immune system to discover the presence of pathogens. More than 10 cytosolic receptors of 
DNA have been identified in recent years, including the cGAS, PYHIN (Pyrin and HIN200 
domain) family proteins AIM2 (absent in melanoma) and IFI16 (interferon-γ (IFNγ)-inducible 
protein 16) [191], which are activate different signaling pathways to expression of  interferons 
and pro-inflammatory cytokines. Pro-inflammatory cytokines are essential for chemical-
mediator to recruitment the particular immune cells to the site of infection. Over 20 forms of 
IFN have been identified, and these have been further classified into three families; types I, 
type II, and type III depend on their different structures, receptor ligation, and biological 
activities [192, 193]. Type I IFNs are the largest family of IFN and include five classes in 
humans, namely IFN-α IFN-β, IFN-ε, and IFN-κ, and IFN-ω [194].  The target receptor for all 
type I IFNs to bind a common cell-surface is known as the type I IFN receptor and the genes 
that encode type I IFNs are located on chromosome 9 in humans [193, 195]. On the other 
hand, IFN-γ is the only type of IFN-II and the gene that encodes this cytokine is placed on 
chromosome 12 [193, 196]. IFN-γ binds another cell-surface receptor, which is identified as 
the type II IFN receptor [197]. Type III are identified recently and contain four types IFN-λ1-
4 [198], its receptors are heterodimeric receptors [199]. 
The IFNs are induced following viral infection by pathogen-associated molecular patterns 
(PAMPs), consist of evolutionarily conserved molecules like nucleic acids, proteins and 
carbohydrates, which are sensed by corresponding pattern recognition receptors (PRRs) [190]. 
In general these innate immune sensors can be classified into two major classes depending on 
their subcellular location. PRRs that recognize extracellular PAMPs are normally found on 
the plasma membrane or endosomal membranes, and contain the Toll-like receptors (TLRs) 
and the C-type lectin receptors (CLRs) [200, 201]. Usually these membrane-bound PRRs are 
mostly expressed in immune cells, such as macrophages and dendritic cells. In another side, 
intracellular PRRs are located in the cytoplasm or nucleus of mammalian cells, and include 
the NOD-like receptors (NLRs; also known as nucleotide-binding domain (NBD) and leucine-
rich repeat (LRR) containing proteins), RIG-I-like receptors (RLRs), and a group of 
intracellular DNA sensors that contains interferon-γ (IFNγ)-inducible protein 16 (IFI16) and 
cyclic guanosine monophosphate-adenosine monophosphate (GMP-AMP) synthase cyclic 
GMP-AMP synthase (cGAS) [202, 203]. The innate immune system identifies the type of 
viral PAMP and triggers mechanisms which stimulate genes responsible for bringing the 
defending cell into an anti-viral state. After sensing viral nucleic acids, the (cGAS) and other 
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innate immune sensors are a highly conserved sensor for cytosolic nucleic acid and structural 
proteins, create the second messenger, cyclic guanosine monophosphate-adenosine 
monophosphate, that activate the stimulator of IFN genes (STING), mitochondrial antiviral 
signaling protein (MAVS) or MYD88, as well as a common set of well-studied serine/ 
threonine kinases and restriction factors [204, 205]. STING activation induce the 
phosphorylation of TANK binding kinase 1 (TBK1) and the following phosphorylation and 
dimerization of interferon-regulatory transcription factors IRF3 and IRF7. Nuclear 
translocation of the IRF3/IRF7 homo-or-hetero dimers will activate IFN-I gene expression. In 
addition, STING activates the IκB kinase (IKK), which phosphorylates IκB family of NF-κB  
 
Figure 2. 9 The activation and recognition of ISGs by cytosolic nucleic acid pattern. Viral double-
stranded (ds) or single-stranded (ss) DNA or RNA is recognized by pattern-recognition receptors 
(PRRs). The foreign DNA sensing goes through AIM2-like receptors (ALRs), such as IFI16, DAI, or 
AIM2 itself, while RIG-I-like receptors (RLR)-RIG-I and MDA5 specialize in RNA detection. cGAS 
is considered the major DNA sensor. 2′-5′-oligoadenylate synthetase (OAS) is an additional sensor for 
foreign RNA. The stimulator of IFN genes (STING) and mitochondrial antiviral-signaling protein 
(MAVS) activate by the DNA or RNA sense, that lead to phosphorylation of interferon (IFN) response 
factors 3 or 7 (IRF3/7), or to phosphorylation and ubiquitin-mediated degradation of IκB. After 
phosphorylation of IRF3/7 or NF-κB, they translocate to the nucleus and activate specific promoters, 
causing expression of IFN as well as a subset of ISGs. Through the JAK-STAT pathway, IFNs induce 
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large expression of ISGs that can be acted as antiviral effectors and negative or positive regulators of 
IFN signaling [206]. 
inhibitors [207]. Phosphorylated IκB proteins are degraded, that lead to releasing NF-κB, 
which enters the nucleus and induces pro-inflammatory cytokines. This signaling cascade 
results in an upregulation of IFN-I against viral infection [208, 209]. After PRRs have been 
activated in cells, IFN-I and IFN-III are secreted and bind, in an autocrine or paracrine 
manner, to the membrane receptor IFNAR (IFN-α/β receptor chain) to induce JAK-STAT 
signal transduction driving the transcription of more than hundreds interferon-stimulated 
genes (ISGs), which encode antiviral proteins [206]. Proteins that are encoded by ISGs play 
important role in targeting and inhibiting the viral life cycle and also regulate innate immune 
sensing and induce the production of cytokines, thereby creating an antiviral state. Cytokines 
and chemokines that are produced following the activation of PRR signals are also essential 
for determining an effective adaptive immune response [203].  
Furthermore, cGAS and STING activity are regulated under normal conditions by post-
translational modifications, such as phosphorylation, ubiquitination, SUMOylation, and 
glutamylation, to prevent sustained innate immune activation [210-213]. The activation of 
intracellular sensing pathways by endogenous DNA is associated with the pathogenesis of 











3 Objectives of this work 
Porcine organs are of significant importance for xenotransplantation. However, porcine cells 
contain numerous Porcine Endogenous Retroviruses (PERVs) that can form replication 
competent particles. The risk of PERV transmission to various human cells is relevant during 
xenotransplantation, because PERVs are integrated within the genome of all pigs and the 
ability of PERVs to infect human cells has been shown in vitro. 
The first objective of the work is to investigate the restriction activity of SAMHD1 against 
PERV-A/Cs infection of human cells at the reverse transcription step. For this purpose, 
replication competent PERV-A/C viruses should be used. Furthermore, selected human 
immune primary cells should be used as recipient cells, as these are known to be particularly 
obstructive for HIV-1 and other retroviruses by restriction factors like SAMHD1. The 
analysis should include an investigation into the relation between the amount of the expressed 
SAMHD1 and its restriction function for PERV-A/C infection. Another topic should be the 
analysis of the mode of restriction by SAMHD1. It has to be determined whether it’s the 
presumed depletion of the dNTP pool in the cytoplasm. This could be analyzed by adding 
exogenous deoxynucleosides to the human primary cells. Moreover, the investigation of the 
SAMHD1 restriction should be extended to resting and activated human CD4+ T-cells. 
Since no experiments had yet been performed with the innate immune response to PERVs 
infection, the second general aim is to study the IFN response through monitoring induction 
of IFN stimulated genes (e.g. CXCL/IP-10, IFN-β, and ISG-54) of human immune primary 
cells infected by PERV-A/Cs. Monocytes, MDMs and MDDCs should be used to determine 
the induction of an innate immune response against PERV-A/C infection. In case of a 
response, the additional aim is to identify the signaling pathways, which play a role in the 
type I IFNs response in human primary cells infected by PERV-A/Cs. To investigate that, 
cells might be pretreated with different inhibitors including a JAK-inhibitor (AT9283), TBK1 







4 Materials and Methods 
4.1      Materials  
4.1. 1   List of Human cells 
Type of cells                                          Origin                                                  Medium 
Hek 293T               Kidney                                                          MDEM 
THP1                                                Acute monocytic leukemia                             RPME 1640 
Monocyte                                                         PBMC                          DC 
MDDC                PBMC                           DC 
MDM              PBMC                          DC 
CD4+T-Cells                  PBMC                        RPME-1640 
 
4.1. 2   List of bacterial strain 
   Bacteria Strain                                                            Genotype                            Manufacturer  
OneShot® Top10 chemically competent 
cells                    
    E-coli                                Invitrogen 
OneShot® Top10 electrical competent 
cells                                                        
    E-coli                                Invitrogen  
 
4.1. 3    List of plasmids and vector backbones 
Constract/ plasmid                                     Description                                         Manufacturer 
VSV-g                                                        Functional envelope plasmid, 
containing promoter and env 
gene of the vesicular 
stomatitis virus glycoprotein 
                      Addgene  
Gag-Pol Precursor HIV-1 proteins                       Addgene 
Rev  RNA-transporter                        Addgene 
VPX                                    Accessory protein find in 
HIV-2 and SIV-mac239 
          




4.1. 4    List of enzyme  
Name  Manufacturer 
Proteinase K Biolab 
Benzonase Sigma 
DNase Ambion 
RNase inhibitor Thermofisher 
Reverse transcriptase  Thermofisher 
TaqMan hot-start Polymerase Bioline 
Trypsin   Biochrom 
4.1. 5    List of Antibodies 
Name  Manufacturer 
α- SAMHD1 (mouse) Origene 
α- P-SAMHD1 (rabbit) Cell-Signaling 
α- MYC (mouse)                          Sigma 
α- Tubulin (mouse) Sigma 
α- GAPDH (mouse and rabbit) Sigma 
α- IRDye® 680LT Goat anti-Mouse Li-Cor 
α- IRDye® 800CW Goat anti-Rabbit Li-Cor 
α- P24 HIV-1 (mouse)                  Abecam 
α- CD4+ T-cells biotin cocktail ( human)                                                    Milteny Biotec 
α- CD4+ T-cells microbead cocktail 
(human)                
Milteny Biotec 
α- CD4- FITC (human) BD Biosciences Pharmingen 
4.1. 6    List of cytokinase activators and inhibitors 
Name           Manufacturer 
Human GM-CSF Peprotech 
Human IL-4 Peprotech 






4.1. 7    List of Primers and Probes 
Gene detection  Sequencing Reference 
PERV-Gag -fw            TCCAGGGCTCATAATTTGTC [216] 
PERV-Gag -rev TGGCCATCCAACATCGA [216] 
PERV-Gag -probe FAMAGAAGGGACCTTGGCAGACTTTCT- 
BHQ 
[216] 
pGAPDH -fw       ACATGGCCTCCAAGGAGTAAGA [58, 217] 
pGAPDH-rev  GATCGAGTTGGGGCTGTGACT [58, 217] 
pGAPDH-probe HEX-CCACCAACCCCAGCAAGAGBHQ1 [58, 217] 
IFNB, (ID): Hs01077958_s1 Thermo scientific 
CXCL-10 (ID): Hs00171042_m1 Thermo scientific 
ISG-54 (ID): Hs00533665_m1 Thermo scientific 
GAPDH (ID): Hs02786624_g1 Thermo scientific 
 
4.1. 8    List of medium 
Name  Composition 
DMEM  Medium were supplemented with 10 % fetal calf serum (FCS, 
Sigma-Aldrich), 100 U/ml penicillin, and 100 μg/ml streptomycin. 
RPMI-1640 Medium were supplemented with 10 % fetal calf serum (FCS, 
Sigma-Aldrich), 100 U/ml penicillin, and 100 μg/ml streptomycin. 
DC-medium RPME-1640 medium were supplemented with 5 % human serum, 
100 U/ml penicillin, 100 μg/ml streptomycin,1mM HEPES and 
filtration with sterile filter. 
LB-medium 10 g/l Bacto Tryptone, 5 g/l Bacto Yeast Extract, 8 g/l NaCl, 1 g/l 
glucose; pH 7.2; supplemented with 100 μg/ml ampicillin 
LB-agar 15 g/l Bacto Agar in LB medium; supplemented with 50 μg/ml 
ampicillin. 
S.O.C-medium 20 g/l Bacto Tryptone, 5 g/l Bacto Yeast Extract, 2.5 mM NaCl, 





4.1. 9    List of reagents and buffers 
Name of Buffer  Composition 
Phosphate-buffered saline (PBS) 138 mM NaCl, 2.7 mM KCl, 6.5 mM 
Na2HPO4, 1.5 mM KH2PO4 
HBS buffer (2x) 280 mM NaCl, 50 mM HEPES, 1.5 mM 
Na2HPO4; pH 7.07-7.15; sterilized by 
filtration. 
Running buffer (10x) 30,3 g/l Tris, 144,1 g/l Glycin, 10 g/l SDS in 
1 l aq. dest 
Transfer buffer (10x) 100 ml 10x Tris-Glycin Puffer, 200 ml 
Methanol in 1 l aq. dest. 
RBC lysis buffer NH4Cl 8.02gm,NaHCO3 0.84gm,EDTA 
0.37gm, QS to 100ml with Millipore water 
NP 40 lysis buffer 50 mM Hepes, 150 mM KCl, 2 mM EDTA, 
0,5 % NP40 
Washing buffer 10% 10x PBS and 0.1% tween20 in aq. dest 
Blocking buffer 5 % [w/v] milk powder and 0.05% tween20 
in PBS. 
MACS buffer 0.5%FBS and 2mM EDTA in PBS 
Carbonate buffer 8.4 g of Sodium bicarbonate, 10.6 g sodium 
carbonate in 500ml distilled water. 
Phosphat-Citrat buffer (0.15 M, pH 5.0) 8.15 g of Na2HPO4-2H2O, 9.336 g of Citric 
acid in 800 mL of distilled water. 
 
 4.1. 10    List of kits  
Kit                                    Manufacturer 
QIAGEN Plasmid Maxi Kit                                     QIAGEN 
RNeasy Mini Kit                                     QIAGEN 
RevertAid H Minus First Strand cDNA 
Synthesis 





4.1. 11    List of reagents and chemicals 
Name  Manufacturer 
Ethanol Roth 
DMSO Sigma 
Ethidium bromide Sigma 
Sodium Dodecyl Sulfate Sigma 
Tris-HCl 0,5 M Sigma 
Tris-HCl 1,5 M Sigma 
TEMED Sigma 
Polyethylenimin (PEI) Polysciences 
Tween 20 Sigma 
Milchpulver Sigma 
Sulfuric acid H2SO4 Merck 
SensiFASTTM Probe No-ROX Master 
Mix 
Bioline 
Loading Dye 4x Novex 
PageRulerTM prestained protein DNA 
Ladder 
Thermo Fisher Scientific 
GeneRulerTM 1 kb+ DNA Ladder Thermo Fisher Scientific 
Nitrocellulose Membrane Bio-Rad 
Tryban blue Sigma 
APS Sigma 
 
4.1. 12    List of instruments  
Name  Manufacturer 
CFX96 TouchTM Bio-Rad 
Odyssey LI-COR 
Nanodrop 1000 Thermo Fisher Scientific 
Stratagene MX3000P Agilent Technologies 
Centrifuge 5415 R Eppendorf 
Microscope Eclipse TS100 Nikon 
Centrifuge 4K15 Sigma 
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Thermomixer compact  Eppendorf 
Vortex Mixer  VWRTMinternational 
LUMIstar Omega BMG LABTECH GmbH 
Gel-reader PHASE 
FACS-Calibur  Becton-Dickinson 
MJ MiniTMThermalcycler Bio-Rad 
Water bath  Köttermann 
ELISA Reader Sunrise Tecan Group 
Centrifuge 5804R Eppendorf 
MACS Multi-Stand Miltenyi Biotec 
HB-500 MinidizerTMHybridization Oven UVP 
GFL 3016 Theoder Karom 
POWERPACHC  Bio-Rad 
Magnetic stirrer Ikamag IKA 
Balance PR803 METTLER TOLEDO 
Pipettes  Eppendorf 
Vacusafe compfort IBS Integra Bioscience 
CO2 Incubator Thermo scientific 
Safety Cabinets HERAsafe HSP Kendro laboratory products 
MACS holder Milteny Biotec 
 
4.1. 13    List of consumables 
Name  Manufacturer 
Cell culture flasks TPP 
Cell culture plates (6-well, 12-well, 96well) Thermo Fisher Scientific 
Centrifuge tubes (1,5ml, 15 ml, 50 ml) TPP 
Petri dishes TPP 
Multiplate® PCR PlatesTM Bio-Rad 
Glass-pipets (5ml, 10ml, 25ml) TPP 
Pipet tips Thermo Fisher Scientific 
Cell Scrapers TPP 
Minisart single use filter unit. Sartorius stedim biotech 
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Rapid filter max Tpp 
Syringes  Braun 
Gloves  Microflex NeoTouch 
LS column Milteny Biotec 
 
4.1. 14    List of software 
Name  Manufacturer 
CFX Maestro Bio-Rad 
Easy Reader (ELISA) Developed by Dr. S. Norley, RKI 
Geneious R11 Bio matters 
NanoDrop® ND-1000 Thermo Fisher Scientific 
MxPro QPCR Software Stratagene 















4.2    Methods 
4.2.1 Cell culture 
4.2.1.1  Cultivation of HEK-293T cells 
“HEK cells” is the short term for human embryonic kidney cells, a cell line derived from 
human embryonic kidney cells. HEK-293T cells are often used in the development of virus 
vaccines, chemotherapeutics and for the production of recombinant adenovirus-vectors and 
are a comparably easy-to-handle cell line. For this work, HEK-293T cells were used for virus 
production and were grown in 75 cm2 or 150 cm2 cell culture flasks at 37°C, 5% CO2 and 
98% humidity. 
HEK-293T cells form an adherent monolayer in the cell culture flask and should hence not 
exceed 90% confluency. If the bottom of the flask is completely covered, cells are not able to 
grow anymore due to contact inhibition. Therefore, HEK-293T cell were split 3 times per 
week at a 1:10 ratio. First the old media was aspirated and the cells were washed twice with 
10 ml (75 cm2) or 20 ml (150 cm2) PBS. It is important that all FCS is removed, because it 
diminishes the activity of Trypsin, which is used for cell detachment. After washing cells 
were incubated with 1 ml or 2 ml Trypsin/EDTA, respectively, for three minutes at 37°C. Too 
long incubation leads to toxic effects of Trypsin. After incubation trypsin activity was stopped 
by addition of 10 ml or 20 ml media containing FCS, respectively. The cells were singularized 
and split 1:10. At last, 9 ml or 18 ml, respectively, pre-warmed fresh media was added to the 
cells. Cells were then again incubated at 37°C, 5% CO2 and 95% humidity. All works were 
performed under a sterile bench. 
4.2.1.2 Preparation of viral stocks 
In order to infect the human cells, viral stocks should be prepared. For this purpose uninfected 
HEK-293 T-cells were seeded in T25 cell culture flasks. When cell confluency reached 50%, 
medium, PERV A/C was added to the cells. The endogenous PERV A/C was initially isolated 
from porcine PBMC. Cells were then incubated for three days with the viruses afterwards 
they were trypsinized and further cultured in larger flasks for three days. After the 10th day 
post infection cell culture supernatant were harvested five times every 3rd day. Supernatants 
were centrifuged (2000 x rpm, 5 min) and filtered (0.2 μm), and aliquots of 1 ml were freeze 
down in -80C°. Titration of supernatants by using real-time PCR and the relative cDNA levels 
were determined using the DDCT method, normalizing to the CT values of the GAPDH gene.  
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4.2.1.3 Human primary cells isolation and cultivation 
Human peripheral blood mononuclear cells (PBMCs) were purified from healthy blood 
donors (Deutsches Rotes Kreuz Berlin) by ficoll density gradient centrifugation. In tissue 
culture hood, blood was emptied into a 50 ml canonical tube, 25 ml for each tube, and then 
completed with RPMI-1640 free medium to 50 ml. 12 ml Ficoll was added to another 50 ml 
conical tube and carefully the RPMI/ suspension were overlaid onto the ficoll. After that 
conical tubes with blood were centrifuged (2200 x rpm without braking) for 25 minutes in 
table top centrifuge. PBMC appeared as a thin white layer above ficoll and below serum, 
which were removed by pipetting and placed in a new 50 ml conical tube and completed with 
PBS to 50 ml. PBMC with PBS were centrifuged (1600 x rpm) for eight minutes, 
supernatants were removed and added 5 ml RBC lysis buffer (ammonium chloride) to the 
cells pellet for 10 minutes at room temperature to lysis the rest of red blood cells. Cells were 
washed by PBS and centrifuged (1200 x rpm) for five minutes, then PBS supernatants were 
removed and PBMC cells pellet were re-suspended in RPMI-1640 medium. PBMC cells were 
routinely counted using a Neubauer counting chamber and seeded in different cell culture 
flasks and plats depending on the type of primary cells, which differentiated from PBMC 
cells. 
To obtain monocyte cells, PBMC cells were seeded at a density of 5x106 cells/ well in 12 
well-plates for 90 minutes to allow the adherent of cells. DC-medium and suspension cells 
were removed, the plate was washed with warm RPMI-1640 free medium two times, and then 
fresh DC-medium was added. Monocyte cells were adherent with the bottom of the well-
plate. 
Monocyte derived macrophage (MDM) cells were differentiated from Monocyte after isolated 
monocyte from PBMC cells by using 50 ng ml-1 GM-CSF for six days in 12 well-plat. DC-
medium was changed each two days and added 50 ng ml-1 GM-CSF in the same time. 
To differentiated monocyte cells to Monocyte derived dendritic cells (MDDC), PBMC cells 
were seeded at a density of 8x106 ml-1 in cell culture flask (T-150). After 90 minutes cells 
suspension with DC-medium were removed and washed with warm RPMI medium two times. 
Fresh DC-medium was added to the monocyte cells. To differentiated monocyte to MDDC, 
50 ng ml-1 GM-CSF and 20ng ml-1 Interleukin-4 were added to the cells each two days for six 
days. After that floated MDDC were collected and counted. Monocyte derived dendritic cells 
were seeded at a density of 106 cells/ well in 12 well-plates.  
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4.2.1.4 CD4+ T-cells isolation  
Human CD4+ T-cells were isolated from peripheral blood mononuclear cells by negative 
selection as described by the manufacturer (Milteny Biotec). Briefly, after PBMCs were  
isolated from human healthy donors as described in (4.2.1.3)  and cells were counted, the cells 
density were selected depending on the type of experiment. Cells were mixed with MACS 
buffer, biotin-antibody cocktail for 10 minutes at 4°C, and then microbead cocktail for 10 
minutes also at 4°C. LS columns were fixed on the magnetic MACS-holder and the mix cells 
with antibodies were added into the column. In new tube CD4+ T-cells were collected and 
after that counted. Resting CD4+ T-cells were seeded at a density of 106 cells/ well in 24 well-
plates. The 107 cells of CD4+ T-cells were plated in small culture flask for activated with 5 ug 
ml-1 phytohemagglutinin (PHA) and 50 IU ml-1 Interleukin-2. Activated CD4+ T-cells were 
counted and seeded at a density of 106 cells/ well.   
4.2.1.5 THP-1 cells cultivation 
THP-1 was derived from the blood of a one-year old boy with acute monocytic leukemia. The 
THP-1 cell line has high expression of the restriction factor SAMHD1, and to find out the role 
of SAMHD1 in restricting the endogenous retrovirus, THP1 cells were treated with stable 
CRISPER/ Cas9 to knock-out SAMHD1. THP-1 cells transduced with a vector encoding for a 
non-targeting guide RNA served as a control [29]. The cells were differentiated with 30 ng 
ml-1 phorbol 12- myristate 13-acetate (PMA) for 72 h. During this time, cells attach to the 
bottom of the cell culture plates and develop macrophage-like morphology. THP-1 cells were 
cultured in Roswell Park Memorial Institute (RPMI) 1640 medium with 10% FBS.  
4.2.1.6 Storage, thawing and freezing of THP-1 and 293T cells 
Cells were stored in nitrogen. Cells were thawed quickly in a 37ºC-water bath. Using a 
floating device, the ampules were kept above the water surface to prevented contamination. 
The thawing content was slightly shaken until only a very small ice-crumb was left in the vial. 
The vial was then sprayed with 70% ethanol all over and its surface was wiped with clean 
tissue in the hood. As soon as the last ice crystals were molten, the suspension was aspirated 
gently and transferred into a culture flask containing 10 ml pre-warmed growth medium. The 
cells were then incubated in the CO2 incubator for 3 hours for adherence. After that the 
medium was replaced with fresh medium. Aliquots of cells were frozen after 10-14 days of 




transferred into a 15 ml Falcon tube. Subsequently, the cells were centrifuged (300 xg; RT, 10 
min). The cell pellet was then carefully re-suspended in culture medium. 1 ml of the cell 
suspension was combined with one ml freezing medium, transferred into a cryovial and 
frozen overnight in a freezing container at -80°C. The next day, the cells were transferred in 
liquid nitrogen for storage. 
4.2.2  Nucleic acid methods and transfections 
4.2.2.1 Transformation 
Transformation of plasmid DNA in bacteria cells, chemically or via electroporation in 
competent cells serves the amplification of plasmid DNA by the growth of the bacteria. For 
this work, only chemical transformation was implemented. 
For chemical transformation, competent E. coli Top10 was used. Competent cells were stored 
at -80°C and thawed before the DNA was added. For re-transformations one ng DNA-sample/ 
50μl bacteria were used. The sample was chilled on ice for 30 min. Then, a heat shock of 
42°C for 45 second followed. After heat shock, the sample was chilled on ice for another 
2min. Then, 200 μl S.O.C. medium was added, and the suspension was incubated for one h, 
650 rpm at 37°C. Then, the suspension was either spread on two LB-Amp plates, with 200 
and 100μl suspension per plate, respectively. Alternatively, the whole suspension was spread 
on one plate for reactions with low probability of success. For re-transformations, only 50 μl 
was spread on one plate. Incubation took place at 37°C overnight. 
4.2.2.2 Isolation of plasmid DNA 
4.2.2.2.1 Mini-preparation 
Small-scale production of plasmid DNA was done in competent E. coli Top10 bacteria. For 
this purpose, a single bacteria clone was picked from an LB plate and put into LB medium 
with required antibiotics. After incubation over night at 37°C in an orbital shaker at 200 rpm, 
two ml of the solution were centrifuged for one minute at 14000 rpm. The supernatant was 
removed and the pellet was resuspended using 100 μl of solution I. Procedure was done 
according to the manufacturer´s manual (QIAprep Spin Miniprep Kit” from Qiagen) and the 
DNA was eluted with 50 μl A.bidest. DNA concentration was measured via NanoDrop 1000 
and the plasmids were stored at -20°C for further use.  
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4.2.2.2.2 Maxi-preparation  
For higher amounts of DNA with a higher purity and for cell culture transfection experiments, 
maxi scale plasmid DNA isolation was performed using Endo-free Plasmid Maxi Kit” from 
Qiagen. Large-scale production of plasmid DNA was done in competent E. coli Top10 
bacteria. A single DNA-colonies were incubated in 5 ml LB-Amp medium at 37°C, 200 rpm 
for ca. 8 h and subsequently 250 μl of the suspension or further cultivated with 250 ml LB-
Amp medium (1:1000) in baffled flasks overnight. It was used also small smear picked from 
plasmid glycerol stock by sterile swab, inserted into 250 ml LB-Amp medium and further 
cultivated over night at 37°C in an orbital shaker at 200 rpm for plasmid isolation. 
Purification was done with help of the “Endo-free Plasmid Maxi Kit” from Qiagen. Procedure 
was done according to the manufacturer´s manual and the DNA eluted with 200 μl A.bidest. 
DNA concentration was measured via NanoDrop 1000 and the samples were stored at -20°C 
for further use. 
4.2.2.3 DNA measurement 
DNA concentration was measured with help of a spectral photometer NanoDrop ND-1000. A. 
bidest was used as a blank. The measurements were automatically done at a wavelength of 
260 nm and 280 nm. 
4.2.2.4  DNA agarose gel electrophoresis  
DNA agarose gel electrophoresis is used for quality control and for separation of DNA 
fragments according to their size and charge. The 0.8% agarose gel was solubilized in 1x TAE 
buffer and completed with 0.5 μg/ml Ethidium bromide (EtBr). EtBr intercalates with the 
nucleotides of the DNA fragments and renders them visible under UV light at a wavelength of 
302 nm. A 6x loading buffer was added to the DNA fragments and the fragments were hence 
separated in a gel chamber filled with 1x TAE buffer at a voltage of 80V. In order to 
determine the size of the DNA fragments, a marker suited for the expected fragment sizes was 
added (GeneRulerTM 1kb). Subsequently a picture of the gel was taken with a gel 
documentation system or the DNA fragments were extracted. 
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4.2.3 Transient transfection and virus normalization 
4.2.3.1 PEI transfection 
HEK-293T cells were used for PEI transfection to produce HIV-1 virus like particles (VLP). 
The day before transfection, HEK-293T cells were seeded in 10 cm cell plates with 
appropriate growth medium (10 ml) and incubated overnight at 37°C, 5% CO2 and 98% 
humidity. On the day of transfection, the cells growth should be 70-75% confluent. The ratio 
of μg PEI to μg DNA should be 1:1 considering transfection efficiency and cytotoxicity. Prior 
to transfection; all reagents were brought to room temperature. Total plasmids of DNA-VLP 
were diluted in serum-free DMEM, and the equal amount of PEI was added to the diluted 
DNA, the total volumes were mixed immediately and incubate at room temperature for 15 
minutes. PEI and DNA were added dropwise to the cell culture dish and then incubated at 
37°C, 5% CO2 and 98% humidity. After 6 h of incubation, the medium was again renewed. 48 
h after transfection the viruses were filtrated and concentrated by ultracentrifugation. 
4.2.3.2 Calcium phosphate transfection 
Transfection of HEK-293T cells using calcium phosphate is a cheap and used for large-scale 
virus production in 10 cm cell plates or 15 cm cell plates. The virus produced by calcium 
phosphate transfection in 293 T-cells is around two-fold higher in titer than virus produced by 
lipofectamine transfection. Calcium Phosphate Transfection was used to produce HIV-1 virus 
like particles (VLP) package with the accessory protein Vpx to degrade SAMHD1. The day 
before transfection HEK-293T cells were seeded in 10 cm cell plates with appropriate growth 
medium (10 ml) and incubated overnight at 37°C, 5% CO2 and 98% humidity. On the day of 
transfection, the cells growth should be 70-80% confluent. In tissue culture hood, dilute 36 μg 
VLP-DNA mixes in sterile, double deionized H2O to the final volume appropriate for the size 
of dish. Then, 75 μl CaCl2 was added and the mixture was well vortexed. For each sample 
were added 750 μl of 2X HBS slowly and drop wise while “bubbling” CaCl2/ water/ DNA 
solution with 2 mL pipet. The reaction was then incubated at room temperature for 30 min. In 
the meantime, the medium in the cell culture flasks was room temperature for five minutes. 
After incubation, the DNA mixture was added dropwise to the cell culture dish and then 
incubated at 37°C, 5% CO2 and 98% humidity. After 6 h of incubation the medium was again 
renewed. 48 h after transfection the viruses were filtrated and concentrated by 
ultracentrifugation. A list of plasmid DNA mixes used for production of pseudotype virus 




Figure 4. 1 The package of Vpx into HIV-1 VLP (VLP system is based on Sunseri et al.). 
4.2.3.3 Purification of virus production by HEK-293T cells after transfection using 
ultracentrifugation 
Purification of transfect cell culture supernatants was carried out via ultracentrifugation. First, 
the transfect cell culture supernatants were collected, filtrated and transferred to 50 ml falcon 
tubes. 5 ml of 20% sucrose was added to the centrifuge tubes (Beckman Coulter) and with 
lowest aid speed of pipet the virus containing supernatant were carefully overlaid onto 
sucrose. The loaded centrifuge tubes were then inserted into the rotor and calibrated to two 
decimal points. Work was done entirely under the sterile bench. The samples were then 
centrifuged at 32’000 rpm, 4°C for 3 h. After centrifugation, the supernatant was discarded, 
and the virus pellet dissolved in 3 ml (for 30 ml transfection volume) MDEM. The solution 
was then transferred to a fresh Eppendorf tube and 10 μl was separated for ELISA to 
normalization. ELISA samples were stored at -20°C, and the vital viruses were stored at -
80°C for later infection. Rotor tubes were sterilized in disinfection reagent for 20 min and 
then washed in 70% EtOH and air-dried afterwards. 
4.2.3.4 Enzyme-linked immunosorbent assay (ELISA) 
In order to normalize virus particles before infection, an ELISA (Enzyme-linked 
immunosorbent assay) was performed. Therefore, a 96-well plate was covered with capture 
antibody and incubated at 4°C overnight. On the next day, the supernatant was discarded and 
the plate rinsed three times with 0.05% Tween. Then, the plate was blocked with PM and 
incubated at 37°C for 45-60 min. In the meantime, virus samples were inactivated with 0.2% 
Tween for 5-10 min at room temperature. After incubation, the PM was discarded and the 
plate firmly tapped but not rinsed. Then, the samples were applied and incubated at 37°C for 
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60 min. After incubation, the plate was rinsed three times with 0.05% Tween. Subsequently, 
the primary antibody was applied and the plate was incubated 60 min at 37°C. Afterwards, the 
plate was rinsed three times with 0.05% Tween and the secondary antibody was applied and 
the plate was again incubated at 37°C for 60 min. After this last incubation step, the plate was 
rinsed three times with 0.05% Tween. In the next step, the stain was added and the plate 
incubated for 10-15 min at room temperature until staining became clearly visible. The 
reaction was finally stopped with H2SO4. The plate was then read in an ELISA reader system. 
All reagents used and their volumes are listed in table (4.1.11). 
4.2.4 Infection Assay 
4.2.4.1 PERV infection of MDDC 
Monocyte derived dendritic cells were isolated and differentiated from PBMCs. New fresh 
DC medium was added before infection procedure. MDDC were treated in two wells in each 
12 well-plate by 10 µM azidothymidine (AZT) one hour before PERV and HIV-1 VLP were 
added to inhibit the virus revere transcription, therefore AZT served as control. Three hours 
before PERV was added, Vpx-containing or controls VLP were added to delivery Vpx into 
the MDDC cells in order to degrade SAMHD1. MDDC were spin-infected with 105.7 TCID50 
ml-1 of PERV-A/C virus treated for 10 min with 25 U Benzonase ml-1 at a room temperature 
to remove contaminating plasmid DNA. After 40 hours, medium was removed, and cells were 
washed two times with PBS. Cells were harvested with 500 µl PBS, collected and transferred 
into two Eppendorf tubes. Cells were centrifuged and stored the pellet at -20°C. Cells in one 
tube were quantified by qPCR to detection PERV-A/C cDNA. The other cell pellets were 
used for western blot to detect SAMHD1. 
In another experiment, MDDCs were treated with one μM deoxynucleotides (dN) (dA, dG, 
dC, dT) at a concentration of one mM for 3 hours before infection with PERV-A/C. The 
exogenous deoxynucleotides increased the reverse transcription products. After that, cells 
were coinfected with HIV-1 VLP, then infected with PERV-A/C virus treated for 10 min with 
25 U Benzonase ml-1. Six hours later, the deoxynucleotides and viruses were washed out and 
removed with medium and fresh DC-medium was added to the cells. After 40 hours medium 
was removed, cells were washed with PBS, harvested, collected, and transferred into two 
Eppendorf tubes. MDDCs were centrifuged and the pellet stored at -20C°. Cells in one tube 
were quantified by qPCR to detection PERV-A/C cDNA. The other tube cells were used for 
western blot to detect SAMHD1. 
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4.2.4.2 PERV infection of monocyte and MDM cells 
 For differentiated PBMCs to monocytes, cells were plated in a 12-well culture plate at a 
density of 5x106 cells/ well, after 90 minutes cells were washed two times with warm free 
RPMI-medium. MDMs were differentiated from monocytes by adding 50 ng ml-1 GM-CSF 
for six days. Monocytes and MDMs were treated with AZT and VLP before infection with 
105.7 TCID50 ml
-1 of PERV-A/C. After 40 hours, medium was removed, and cells were washed 
two times with PBS. Cells were harvested with 500 µl PBS, collected and transferred into two 
Eppendorf tubes. Cells were centrifuged and stored the pellet at -20°C. Cells in one tube were 
quantified by qPCR to detection PERV-A/C cDNA. The other cell pellets were used for 
western blot to detect SAMHD1. 
4.2.4.3 PERV infection of resting and activated CD4+ T-cells 
CD4+ T-cells were isolated from PBMCs by magnetic negative selection. Resting and 
activated CD4+ T-cells were seeded in the 24-well culture plates at a density of 106 cells/ well. 
Cells were treated with 1uM deoxynucleotides (dN) (dA, dG, dC, dT) at a concentration of 
one mM for 3 hours before infection with PERV-A/C. All of these cells were spin-infected 
with PERV A/C treated for 10 min with 25 U benzonase ml-1 at a room temperature in the 
presence or absence of 10 µM azidothymidine (AZT). Six hours later, the deoxynucleotides 
and PERV-A/C virus were washed out and removed with medium and fresh RPMI medium 
was added to the cells. After 40 hours medium was removed, cells were washed with PBS, 
harvested, collected, and transferred into two Eppendorf tubes. Cells were centrifuged and 
stored the pellet at -20°C. Cells in one tube were quantified by qPCR to detection PERV-A/C 
cDNA. The other cell pellets were used for western blot to detect SAMHD1. 
4.2.4.4 PERV infection of THP-1 cells 
THP-1 cells were seeded at a density of 1x106 cells/ well and differentiated with PMA for 72 
h into macrophage. PMA was washed out and added fresh RPMI medium into the cells. THP-
1 cells were infected with PERV-A/C treated for 10 min with 25 U benzonase ml-1 at a room 
temperature. The PERV cDNA were quantified by RT-PCR after 40 h post-infection. 
4.2.5 DNA extraction 
In order to prepare DNA samples after infection, the DNA isolation was based on proteinase 
K lysis. The cells pellets were frozen at -80°C and thawed at 60°C three times. Proteinase K 
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(dil. 1:100 PBS) was added to the pellet, then pellet was good mixed with proteinase K and 
incubated for 2 hours at 56°C. The proteinase K activity was inactivated by heating at 98°C 
for 15 min. Cells were used for quantified PERV cDNA by RT-PCR. 
4.2.6 Quantitative RT-PCR 
Viral cDNA and cellular DNA were analyzed for the porcine endogenous retrovirus PERV 
Gag as well as the housekeeping gene GAPDH. For quantification of PERV pro-viral DNA 
the primers Gag-for and Gag-rev located in the Gag gene and a specific PERV-Gag probe 
were used in a duplex real-time PCR. The reference gene GAPDH was amplified with the 
primers GAPDH-for and GAPDH-rev and quantified using an hGAPDH-probe. The RT-PCR 
primers, probes and the cycling conditions for PERV sequences consisted of as in the table 
(4.15). 
 
Time Temperature Cycles 
5:20 min 95°C 1 
30 sec 95°C 45 
30 sec 56°C 45 




Quantitative RT- PCR was done using the snsiFAST TM probe No-ROX qRT-PCR Kit see 
the table of PCR reaction. Levels of cDNA were measured using the ΔΔCT method, 
normalizing to the CT values of the GAPDH gene. All   PCR reactions were carried out using 
a Real-Time PCR System Stratagene MX3005P and BioRad CFX96. 
4.2.7 Fluorescence activated cell sorting (FACS) 
Fluorescence activated cell sorting (FACS) was used to measure the purity of isolation CD4+ 











PERV Gag-probe 0,5ul 
 
GAPDH For 0,5ul 
 










Table 4.2.1 Reactions mix and cycle conditions for 
PERV quantitative PCRs. 
42 
 
cells were aliquoted in Eppendorf tubes at a density of 5x105 cells. Cells were incubated with 
the FITC anti-human CD4 for 2 h at 4°C. Cells were washed, and added goat anti-mouse IgG-
FITC secondary antibody into the cells for 1h at 4°C. Cells were fixed with 1% 
paraformaldehyde for 1 h at 4°C. Fixation was removed and cells were washed and 
resuspended in FACS buffer and stored at 4°C. Measurements were performed using a FACS 
calibur (BD Biosciences) and 104 cells of each sample were measured. 
4.2.8 RNA isolation 
RNA isolation from human primary cells was performed using the RNeasy mini-kit (Qiagen) 
as described by the manual of manufacturer to measure the relative mRNA interferon 
response in primary cells after PERV-A/C infection. Depending on the cell number, RNA was 
eluted in 30-50 μl nuclease-free H2O and concentration was determined using a 
NanoDrop1000 spectrometer, and stored at -80°C. 
4.2.9 cDNA synthesis and qPCR  
Reverse transcription of isolated cellular RNA was performed with a RevertAid H minus first 
strand cDNA synthesis kit. DNase was used to digest the contaminated DNA with RNA, for 
that RNA was incubated with DNase at 37°C for 30 min. The DNase reaction was stopped by 
DNase inactivation reagent (dil.1:10) (Turbo DNA free kit), incubated for 5 min at RT. The 
RNA reverse transcription reaction was started by primer annealing, 1 µl oligo dt primer and 
3,2 µl H2O were added to the reaction, then incubated at 65°C for 10 min then transferred the 
reaction tube on the ice to cold. After that, 4 µl 5x reaction buffer, 1 µl RNase inhibitor, 2 µl 
dNTP-mix and 1 µl reverse transcriptase were added to the tube. Reaction tubes were 
incubated at 42°C for 2 h, then heat inactivated at 70°C for 5 min. Quantitative PCR was 
performed to find out the interferon induction with PERV-A/C infection normalizing to the 
housekeeping gene GAPDH. For quantification of IFN-beta, ISG54 and CXCL-10 (IP-10), 
their primers and probes were used in a duplex real-time PCR. The volume qPCR reaction 
and thermal cycle were as in the table (4.16).  
Levels of mRNA were measured using the ΔΔCT method, normalizing to the CT values of 
the GAPDH gene. All   PCR reactions were carried out using a Real-Time PCR System 




Master mix sensiFAST 7,5ul 













4.2.10     Protein chemistry 
4.2.10.1 Measurement of protein concentration 
Protein quantification was performed using the Pierce BCA™ protein Assay kit. The method 
is based on the reduction of Cu2+ ion to Cu1+ by proteins in an alkaline medium (The Biuret 
reaction). The amount of the reduced cuprous ion is proportional to the amount of protein 
present in the solution. The chelation of bicinhoninic acid (BCA) with Cu2+ ions produces a 
purples-colored complex exhibiting high absorbance at 562 nm. The working reagent was 
prepared by mixing BCA reagent A with BCA reagent B (50/1). As standard, albumin (BSA) 
was used with concentrations of 0, 25, 125, 250, 500,750,1000,1500 and 2000 μg/ml. 
afterwards 25 μl of each sample to measure as well as the standards were added into a 96-well 
plate and mixed with 200 μl working reagent each. After 30 min incubation at 37°C, 
absorbance was measured on an ELISA Reader at 560 nm with reference 562 nm. Protein 
concentrations were calculated using the BSA-standard curve. 
4.2.10.2  Preparation of cell lysate 
To prepare samples for western blotting, whole cells were lysed to release the proteins of 
interest using NP-40 lysis buffer and Proteinase inhibitor. Cells were washed 3 times with 
cold PBS and centrifuged at 2000 rpm for 5 minutes. Lysis followed by adding lysis buffer 
into the cells and incubating on ice for 10 minutes. Lysates were centrifuged at maximum 
speed for 10 minutes at 4°C to pellet the cells debris and protein containing supernatant was 
recovered and frozen down at -20°C till used. 
Time  Temperature Cycles  
15 min 95°C 1 
10 sec 95°C 39 
20 sec 60°C 39 
    Table 4.2.2 Reactions mix and cycle conditions for IFN-response quantitative PCRs. 
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4.2.10.3  Western blot 
To analyze the amount of SAMHD1 proteins in the cells, immune blot was performed. 
Infected human cells pellets were analyzed after 40 h after infection using NP-40 lysis buffer. 
Twenty micrograms of each protein lysate were boiled in Laemmli buffer, loaded on 12% 
polyacrylamide gels, subjected to SDS-polyacrylamide gel electrophoresis (PAGE) and 
electro-blotted onto nitrocellulose membranes. After protein transfer, membranes were 
blocked for 1 h at room temperature in a 5% solution of milk powder (Roth) in 1× PBS-T 
with 0.05% Tween 20, washed in 3× PBS-T and incubated 1 h at room temperature or 
overnight with an anti-SAMHD1 mouse MAb and the loading control anti-GAPDH or tubulin 
at 4°C, after that washed in 3× PBS-T. The secondary antibody IRDye 800 or 680 goat anti-
mouse or anti-rabbit were added to the membranes for 1h at room temperature, and then 
















5  Result 
Since human SAMHD1 limits the replication of a variety of endo- and exogenous 
retroviruses, we reasoned that the transmission of PERV-A/C from pig organs to human 
recipients during xenotransplantation may be restricted by SAMHD1. To assess the role of 
human SAMHD1 in restricting the PERV-A/C virus, we used an assay in which human 
SAMHD1 expressing cells (primary cells: monocytes, MDMs, MDDCs, CD4+ T-cells and the 
THP-1 cells line) were incubated with Vpx-containing or Vpx-lacking VLP and then infected 
with PERV-A/C. In this work, it was also focused on the IFN-I response (IFN- β, ISG-54 and 
CXCL-10/ IP-10) after stimulation of human primary cells through PERV-A/C infection.  
5.1 The role of human SAMHD1 in restricting PERV-A/C in human 
primary cells and THP-1 macrophages 
5.1.1 SAMHD1 restricts PERV-A/C RT-products in monocyte derived dendritic 
cells (MDDCs) 
The antiviral activity of SAMHD1 was found to be regulated by cell cycle-dependent 
phosphorylation, enabling SAMHD1 to restrict retrovirus infection only in non-dividing cells 
[218]. To confirm the SAMHD1 restriction for PERV-A/C in non-cycling cells, monocytes 
were isolated from healthy donor PBMCs (isolated from buffy coats derived from anonymous 
donors acquired from Deutsches Rotes Kreuz Berlin) and were differentiated to MDDCs 
using 50 ng ml-1 GM-CSF and 20 ng ml-1 Interleukin-4. After six days of differentiation the 
MDDCs were infected with 105.7 TCID50 ml
-1 of PERV-A/C. PERV-A/Cs were initially 
isolated from porcine PBMC, grown on 293T cells and were treated with benzonase before 
infection. The cells were coinfected in the presence of 100-ng p24 HIV-1 derived virus-like 
particles (VLP) modified in P6 in order to package or not to package the Vpx protein of 
SIVmac239. To control the measurement of reverse transcripts, the RT-inhibitor AZT (10 
μM) was added in parallel. PERV reverse transcripts were quantified by qPCR 12 h, 24 h and 
40 h post infection to find out the suitable time to determine the amount of PERV-A/C cDNA 
product. The qPCRs have been performed using the primers and probes of PERV Gag, in 
parallel with the primers and probes of the housekeeping gene GAPDH. Relative cDNA 
levels were determined using the ΔΔCT method, normalizing to the CT values of the GAPDH 
gene. The results show that addition of Vpx alleviated reverse transcription in MDDC and the 
PERV-A/C cDNA products were higher after 40 h post infection in comparison to 12 and 24 
h (Fig.5.1). Therefore, 40 h post infection was selected as a time to measure the PERV-A/C 
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reverse transcription product. As expected, AZT lowered the amount of RT products in the 






Figure 5. 1 SAMHD1 restricts PERV A/C infection in MDDCs 40 h post-infection. MDDCs 
derived from two healthy donors were infected with PERV A/C in the presence of Vpx-containing or 
lacking VLPs. Addition of the reverse transcriptase inhibitor AZT served as control. PERV A/C 
reverse transcripts were quantified relative to GAPDH 10 h (Fig.5.1a), 20 h (Fig.5.1b) and 40 h 
(Fig.5.1c) post infection by qPCR. The reverse transcripts were quantified relative to GAPDH using 
the ΔΔCT method for PERV A/C. The amounts of RT-products quantified in cells infected in the 
absence of Vpx were set to 1. Mean values and SEM are shown.  
To confirm the block of PERV reverse transcription in MDDCs by SAMHD1, the experiment 
was repeated on six additional donors. After differentiation, MDDCs were pretreated with 
AZT and HIV-1 VLP containing or lacking the Vpx protein, and then cells were infected with 
105.7 TCID50 of PERV-A/C, treated with benzonase. AZT treated and heat-inactivated PERV-




























































































































primers and probes of PERV Gag, in parallel with the primers and probes of GAPDH. PERV-
A/C reverse transcripts were quantified by qPCR 40 h post infection. Relative cDNA levels 














Figure 5. 2  SAMHD1 restricts PERV A/C cDNA production in MDDCs. a) MDDC derived from 
six healthy donors were infected with PERV A/C in presence of VPX-containing or lacking VLP. 
Addition of the reverse transcriptase inhibitor AZT or heat inactivation of the virus served as controls. 
PERV A/C reverse transcripts were quantified relative to GAPDH 40 h post infection by qPCR. The 
reverse transcripts were quantified relative to GAPDH using the ΔΔCT method for PERV A/C. The 
amounts of RT-products quantified in cells infected in absence of Vpx were set to 1. Mean values and 
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SAMHD1 in MDDCs after treated with VLP packaging Vpx or lacking Vpx and infected with PERV 
A/C. The cell lysates were collected 40 h post infection, GAPDH served as a loading control. The 
proteins were visualized by an Odyssey imaging system. 
Quantification of PERV-A/Cs cDNA in MDDCs revealed that Vpx lead to about 100 fold 
more cDNA (Fig.5.2). The PERV cDNA levels in MDDCs pretreated with VLPs containing 
Vpx and infected with heat inactivated virus were about 200 fold lower than in the same cells 
infected with regular PERV. AZT lowered the amount of RT products in the presence of Vpx 
substantially indicating the specificity of the cDNA analysis (Fig.5.2). Immunoblot analyses 
for six donors using an anti-SAMHD1 MAb were performed to confirm the Vpx-mediated 
degradation of SAMHD1 in the infected MDDCs with all six donors (Fig. 5.2. lower panel). 
As secondary antibodies IRDye 800 anti-mouse was used. The proteins were visualized by an 
Odyssey imaging system. The results show that Vpx caused substantial degradation of 
SAMHD1 in all six donors compared to control no-Vpx samples. GAPDH served as a loading 
control. 
5.1.2 The restriction of PERV A/C cDNA depends on the amount of SAMHD1 
Exposure of differentiated MDDCs to VLP-Vpx relieves restriction to PERV-A/C RT-
products (Fig.5.2.a). To investigate if this restriction is based on the expression of SAMHD1, 
MDDCs of two donors were treated with increasing amounts of VLPs containing Vpx (3.3 ng, 
10 ng, 30 ng, and 90 ng) or cells were treated with control VLP with no Vpx. AZT was added 
to inhibit the reverse transcription. The qPCR results show that increasing amounts of VLPs 
delivering Vpx lead to increased PERV reverse transcription (Fig.5.3). SAMHD1 degradation 
in the immune blot of two donors correlated with the amounts of VLP-Vpx added (Fig.5.3, 
lower panel) and lead to an increase in PERV cDNA products in MDDCs. AZT decreased the 
amount of PERV-A/C reverse transcription in the present of 90 ng Vpx and in the absence of 
SAMHD1 (Fig.5.3). 
5.1.3 The addition of exogenous deoxynucleosides (dN) to MDDCs alleviated the 
SAMHD1 - mediated restriction for PERV-A/C 
The role of SAMHD1 in regulating the dNTP pool in primary MDDCs was tested. To 
determine if PERV-A/C is restricted by the low abundance of dNTPs in MDDC, dNTPs were 
added to the cells. In this case providing dNTP to the MDDCs should prevent the SAMHD1 







Figure 5. 3 The restriction of PERV-A/C RT-product depends on SAMHD1 expression. MDDCs 
of two donors were treated with increasing amount of VLP-Vpx or control VLP with no Vpx 3 h 
before PERV-A/C was added. AZT served as control. PERV A/C reverse transcripts were quantified 
relative to GAPDH 40 h post infection by qPCR, using the ΔΔCT method. The amounts of RT-
products quantified in cells infected in absence of Vpx were set to 1. Mean values and SEM are 
shown. *P<0.05; **P<0.005; unpaired t-test. Immunoblot analysis for two donors to detect the amount 
of SAMHD1 in MDDCs after treatment with increasing amount of VLP+VPX or lacking Vpx and 
infected with PERV A/C, GAPDH served as a loading control. The proteins were visualized by an 
Odyssey imaging system. 
treated with exogenous deoxynucleosides (dN) prior to infection with PERV-A/C. These are 
taken-up and directly converted to dNTP through the salvage pathway of dNTP synthesis, 
increasing the intracellular dNTP pool. MDDCs of three healthy donors were purified from 
the peripheral blood mononuclear cells (PBMCs), after that cells were pre-treated with 1 mM 
dN for 30 min before infection with PERV-A/C and co-infection with VLP+Vpx or empty 
VLP.  
The results show a similar significant increase of PERV reverse transcripts in MDDC treated 
with 1 mM dN compared to addition of VLP+Vpx (Fig.5.4). A combination of dN 
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Figure 5. 4 The addition of exogenous dN to the MDDCs alleviated the SAMHD1 restriction. 
MDDCs were isolated from PBMCs of three healthy donors. Cells were treated with 1 mM dN and 
control VLP or Vpx-containing VLP for 30 min before PERV infection. AZT served as control. PERV 
A/C reverse transcripts were quantified relative to GAPDH 40 h post infection by qPCR, using the 
ΔΔCT method. The amounts of RT-products quantified in cells infected in absence of Vpx were set to 
1. Mean values and SEM are shown. *P<0.05; **P<0.005; unpaired t-test. Immunoblot analysis for 
three donors to detect the amount of SAMHD1 in MDDCs after treated VLP+VPX or control VLP and 
infected with PERV A/C, GAPDH served as a loading control. The proteins were visualized by an 
Odyssey imaging system. 
PERV-A/C reverses transcription. The reverse transcription inhibitor, AZT, prevented the 
PERV-A/C cDNA production in the absent of SAMHD1. In the immunoblot analysis of three 
donors, the results demonstrate the degradation of SAMHD1 by the addition of Vpx 
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The results demonstrate that PERV inhibition in human MDDC can be overcome by 
increasing the dNTP level. This further indicates that the restriction at physiological levels of 
SANHD1 is mediated by SAMHD1. 
5.1.4 SAMHD1 restricts PERV-A/C replication in monocytes 
To test if PERVs reverse transcription is restricted by SAMHD1 in other myeloid cell types, 
primary monocytes were infected from six human healthy donors. Similar to the previous 
experiments, the cells were isolated from PBMCs and infected with normalized PERV-A/C 
supernatants in presence of VLP containing or lacking Vpx to understand the role of 
SAMHD1. Heat-inactivated PERV-A/C served as a negative control for cDNA quantification 
in the real time PCR. The results show that SAMHD1 potently restricts PERV-RT in 
monocytes and the addition of Vpx to the cells leads to SAMHD1 degradation and to a 
profound increase of RT products (Fig.5.5). One of the factors contributing to the apparent 
donor-dependent variability is presumably the efficiency of SAMHD1 downregulation by 
Vpx+VLPs. The result of the immune blot confirms that SAMHD1 is depleted by Vpx in 





Figure 5. 5 PERV-A/C infection was restricted by SAMHD1 in monocytes. Monocytes were 
isolated from six healthy donors. Cells were infected with PERV-A/C for 40 h. Heat inactivated PERV 
served as a control. PERV cDNA was quantified by qPCR and normalizing to the CT value of 
GAPDH using the ΔΔCT method. The amounts of RT-products quantified in cells infected in absence 
of Vpx were set to 1. Mean values and SEM are shown. *P<0.05; **P<0.005; unpaired t-test. 
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treatment with VLP+Vpx or control VLPs without Vpx and subsequent infection with PERV A/C. 
GAPDH served as a loading control. 
5.1.5 PERV-A/C reverse transcription is restricted in MDM by human SAMHD1 
Monocyte derived macrophages from six donors were generated by cultivating freshly 
isolated monocytes in 50 ng ml-1 GM-CSF for six days and changing medium to refresh with 
cytokine every other day. For monitoring SAMHD1 restriction, MDM were infected with 
normalized PERV-A/C after cells pre-treated with VLP containing or lacking Vpx. AZT and 
heat- inactivated PERV was used as a negative control. The delivery of Vpx to the MDM cells 
by VLP to degrade SAMHD1 resulted in an around 20 to 100 fold increase of PERV cDNA 
compared to the control VLP (Fig. 5.6). In MDM cells, which express SAMHD1, PERV-A/C 
is nevertheless reverse transcribed to some extend since AZT treatment resulted in even lower 
PERV-cDNA levels. That means, SAMHD1 might be does apparently not completely restrict 
PERV-A/C in MDM cells. AZT treatment or infection with heat- inactivated virus results in a 
reduced amount of PERV-A/C reverse transcription in the absence of SAMHD1. The immune 
blot of one donor show the knockdown of SAMHD1 by adding the accessory protein Vpx 





Figure 5. 6 SAMHD1 restricts the PERV-A/C cDNA in monocyte derived macrophage (MDM). 
Cells from six healthy donors were differentiated from monocyte to MDM by using the cytokine GM-
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quantified by qPCR relative to GAPDH 40 h post infection, using the ΔΔCT method to calculate the 
fold difference. The amounts of RT-products quantified in cells infected in absence of Vpx were set to 
one. Mean values and SEM are shown. *P<0.05; **P<0.005; unpaired t-test. Immunoblot analysis 
represents one donor to detect the amount of SAMHD1 in MDM after treated with VLP and infected 
with PERV A/C. GAPDH served as a loading control. 
5.1.6 The antiviral activity of SAMHD1 restricts the PERV-A/C RT-product in 
THP-1 cells 
THP-1 cells were used with a stable CRISPR/Cas9 knock-out of SAMHD1 to verify the 
restriction function of SAMHD1 for PERV-A/C. The cells were differentiated with 30 ng ml-1 
phorbol 12- myristate 13-acetate (PMA) for 72 h prior to infection. An immunoblot analysis 
proves the successful knock-out of SAMHD1 in the two clonal cell lines transduced with a 
SAMHD1-specific guide RNA and Cas9 (Fig.5.7). THP-1 cells were infected with 
normalized PERV-A/C supernatants and PERV-A/C cDNA measured 40 h post infection, 
similar to the previous experiments. Heat-inactivated virus served as a control. The results 
show up to 10-fold more PERV-A/C cDNA in two clonal cells lacking SAMHD1 compared 
to the control cells (Fig.5.7). The results confirm the antiviral activity of SAMHD1 in 






Figure 5. 7 SAMHD1 inhibits the PERV-A/C reverse transcription in THP-1 cells. PMA-
differentiated THP-1 cells with a stable CRISPR/Cas9 knock-out of SAMHD1 were infected with 
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products quantified in infected THP-1. CRISPR/Cas9 scramble cells were set to 1. Heat inactivated 
PERV A/C served as a control. SAMHD1 depletion was verified by immunoblot (bottom). GAPDH 
served as a loading control. 
5.1.7 SAMHD1 restricts PERV-A/C replication in resting CD4+ T-cells but not in 
activated CD4+ T-cells 
In addition to myeloid immune cells, SAMHD1 is also expressed to high levels in CD4+ T- 
lymphocytes. Although expressed to similar levels, SAMHD1 is only antiviral against HIV-1 
in resting but not activated CD4+ T-cells [147]. We sought to investigate whether a similar 
restriction profile is observed in PERV infection. To do this, resting CD4+ T-cells were 
isolated from PBMCs of six healthy donors by a magnetic negative selection. The purity of 
the CD4+ T-cells preparation in the different donors was between 85 and 95% as determined 




Figure 5. 8 FACS analysis to determine the purity of the CD4+ T-cells after isolation from 
PBMCs. Anti-human CD4 was added to isolate CD4+ T -cells. Non-treatment CD4+ T-cells with 
antibody were used as a live gate control. The purity of CD4+ T-cells from the total cells is nearly 92% 
(see the percent in the fig.5.8, lower). 
One half of the resting CD4+ T-cells was infected with PERV-A/C after pretreatment with 
VLPs containing Vpx or VLPs without Vpx in the presence or absence of 10μM AZT. The 
other half was activated with 5 ug ml-1 phytohemagglutinin and 50 IU ml-1 interleukin-2 for 
two days and infected similarly. Reverse transcripts in the infected cells were quantified by 
qPCR 40 h post infection. The results indicate that PERV reverse transcription slightly 
increased between two to four fold in cells treated with VPX compared to resting CD4+ T- 
cells not treated with Vpx in the cells (Fig. 5.9). AZT and heat inactivation of the virus 
blocked PERV reverse transcription in cells. Immunoblot analyses for one donor using an 
anti-SAMHD1 MAb were performed to analyze Vpx-mediated degradation of SAMHD. The 




Figure 5. 9 PERV A/C is restricted in resting CD4+ T-cells. Resting CD4+ T-cells from six healthy 
donors were infected with PERV A/C. Reverse transcripts were quantified relative to GAPDH 40 h 
post infection. RT-products quantified in infected cells in absence of Vpx were set to one. Mean 
values and SEM are shown. Immunoblot analysis of one donor (as an example) for SAMHD1 
degaradation in resting CD4+ T-cells after treatment with VLP+Vpx or VLPs lacking Vpx is shown in 












































































































The results with activated CD4+ T-cells show no more difference between cells infected with 
PERV, treated with VLP contain Vpx and cells treated with control VLP (Fig.5.10). Normally 
SAMHD1 lost its antiviral activity by phosphorylation in cycling cells like activated CD4+ T-
cells, therefore SAMHD1 in activated CD4+ T-cells failed to restrict the PERV-A/C reverse 
transcription. The results of the SAMHD1 quantity in the immune blot of activated CD4+ T-
cells were similar to the results of resting CD4+ T-cells, no degradation for SAMHD1 by 




Figure 5. 10 SAMHD1 failed in restricting PERV A/C in activated CD4+ T-cells. Activated CD4+ 
T-cells from six healthy donors were infected with PERV A/C. Reverse transcripts were quantified 
relative to GAPDH 40 h post infection. RT-products quantified in infected cells in absence of Vpx 
were set to one. Mean values and SEM are shown. Immunoblot analysis for one donor to detect the 
degradation of SAMHD1 in activated CD4+ T-cells after treatment with VLP+Vpx, GAPDH served as 
a loading control.  
To compare resting and activated CD4+ T-cells, the amounts of RT-products quantified in 
infected resting CD+ T-cells were set to one. As shown in Figure 5.11, the PERV-A/C cDNA 
product in activated CD4+ T-cells were more with 10 fold higher compared to resting CD4+ T- 
cells. The results indicate that SAMHD1 blocked PERV RT in resting but not activated CD4+ 












































































































Figure 5. 11 PERV-A/C reverse transcription in activated CD4+ T-cells is significantly higher 
than in resting CD4+ T-cells. All six donors shown were infected with PERV-A/C and AZT was used 
as a reverse transcription inhibitor. Mean values and SEM are shown. *P<0.05; **P<0.005; unpaired t-
test. 
5.1.8   The addition of exogenous deoxynucleosides (dN) to resting CD4+ T-cells 
increased reverse transcription of PERV-A/C 
To provide further evidence that the inhibition is exerted by SAMHD1, CD4+ T-cells for three 
donors were isolated from PBMCs by magnetic negative selection. Cells were seeded and 
treated with 1 µM deoxynucleosides for 30 min prior infection. Resting CD4+ T-cells were 
infected with PERV-A/C and 40 h post infection quantified by qPCR. The result indicated 
that 1 mM dN significantly increased PERV cDNA levels in resting CD4+ T-cells (Fig.5.12a). 
At this high dN concentration AZT has lost its inhibitory effect for reverse transcription in 
resting CD4+ T-cells. From this result, it can be deduced that SAMHD1 has the ability to 
inhibit the PERV-A/C replication cycle at reverse transcription by depletion of the 
intracellular pool of dNTP. The Western blot shows the amounts of expressed SAMHD1 for 
three donors in resting CD4+ T-cells (Fig.5.12a, lower panel).  
The activated CD4+ T-cells were infected with PERV-A/C after pretreatment with 1mM 
deoxynucleosides. The results show that in contrast to resting CD4+ T-cells, the addition of 
1mM of deoxynucleosides does not induced PERV-A/C reverse transcription (Fig.5.12.b). 
The Western blot shows the amounts of expressed SAMHD1 for three donors in activated 















































































In summary the resting CD4+ T-cells can be restricted the PERV-A/C infection and the  block 
could be relieved by addition of 1 mM deoxynucleosides during infection, this intervention is 
well known to overcome the enzymatic activity of SAMHD1. In contrast, activated CD4+ T-






Figure 5. 12 PERV-A/C reverse transcription is increased with increased level of intracellular 
dNTP in resting CD4+ T-cells. CD4+ T-cells were isolated from PBMCs by magnetic negative 
selection and either used as resting (a) or activated cells (b). Both types of CD4+ T-cells were treated 
with 1 mM dN or just medium and infected with PERV-A/C. AZT has been used as a reverse 
transcription blocker and PERV-heat inactivation served as a control. PERV-A/C RT-products were 
identified by real time qPCR 40 h post infection. The amounts of RT-products quantified in cells 
infected with PERV-A/C in absence of dN were set to 1. ΔΔCT method was used to calculate the fold 
difference to GAPDH. Mean values and SEM are shown. *P<0.05; **P<0.005; unpaired t-test. The 
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5.2 Innate immune response to PERV  
The innate immune response is the first defense line in the human body against a virus and 
other infections. It is important to know the response from human immune primary cells to 
PERVs infection, especially in the case of xenotransplantation. To assess the interferon 
response to PERV infection, PBMCs were isolated from healthy human donors and 
differentiated into monocytes, MDDCs and MDM cells. Cells were infected with PERV-A/C 
after pretreatment with virus like particles containing Vpx (VLP+Vpx), control VLP without 
Vpx or without any pretreatment. In case of a response, we aim to identify the sensors and 
signaling pathways, which are involved in the type I IFNs response in human primary cells 
infected by PERV-A/C. 
5.2.1 PERV induced the production of CXCL-10 (IP-10) but not INF-B and ISG-54 
in MDDCs 
CXCL-10 is induced in various cell types during infection by pathogens. Immune primary 
cells including monocytes, macrophage, T-lymphocytes, natural killer (NK) cells are 
responsible for the greatest proportion of IP-10 expression [219]. To determine the CXCL-10 
response to PERV-A/C infection, MDDCs were differentiated from monocytes of human 
healthy donors and seeded in 12-well plates. Cells were pretreated with VLP+Vpx or control 
VLPs and then cells were infected with benzonase treated PERV-A/C. 48h post infections, 
RNAs were isolated and the relative differences of CXCL-10 mRNA were quantified by real 
time PCR. Heat-inactivated virus served as a negative control. The results show that PERV-
A/C increased the CXCL-10 induction over 100 folds compared with non-infected cells.  
Treatment with VLP+Vpx or empty VLP alone did not cause significant CXCL-10 induction 
(Fig.5.13). The expression or lack of SAMHD1 plays no important role in the induction of 
CXCL-10 by PERV-A/C. Heat-inactivated PERV-A/C lowered the CXCL-10 induction in 
infected cells, as expected (Fig.5.13).  
In contrast to CXCL-10, the response of IFN-β in MDDCs to PERV-A/C infection was not 
significant compared to the non-infected cells and to the positive control (poly I.C). PERV-
A/C induced IFN- only slightly in one donor (fivefold compared with mock cells). No effect 




Figure 5. 13 PERV-A/C induces CXCL-10 in MDDCs. MDDCs were infected with a PERV-A/C 
recombinant virus after pretreatment with virus like particles containing Vpx (VLP+Vpx), control 
VLP, poly I.C or without pretreatment. The CXCL-10 relative mRNA activity was quantified by real 
time PCR. Heat-inactivated PERV served as a negative control and poly I.C served as a positive 
control. The amounts of mRNA quantified in non-infected cells were set to 1. ΔΔCT method was used 
to calculate the fold difference. Mean values and SEM are shown. *P<0.05; **P<0.005; unpaired t-
test.  
 
Figure 5. 14 PERV-A/C is incapable to activate IFN-β in MDDCs of three donors. MDDCs were 
infected with PERV-A/C. Poly I.C has used as a positive control and heat-inactivated PERV was used 
as a negative control. The amounts of mRNA quantified in non-infected cells were set to 1. ΔΔCT 
method was used to calculate the fold difference. Mean values and SEM are shown. *P<0.05; 













































































































































The same results were found regarding the ISG-54 response to PERV-A/C infection. Only a 
weak non-significant two to three fold mRNA increase of ISG-54 was induced after MDDCs 
infection with PERV-A/C. Addition of VLP did not result in any significant changes 
(Fig.5.15). Heat-inactivated virus served as a negative control and poly I.C as a positive 
control. 
 
Figure 5. 15 ISG-54 is not induced by PERV-A/C in MDDCs. Amounts of ISG-54 mRNA in non-
infected cells were set to 1. ΔΔCT method was used to calculate the fold difference. Mean values and 
SEM are shown. *P<0.05; **P<0.005; unpaired t-test. 
5.2.2 CXCL-10 induction by PERV-A/C infection is significant in MDM 
To demonstrate that CXCL-10, IFN-β and ISG-54 responses induced to PERV-A/C infection, 
are also present in other cell types we performed experiments in MDM of three healthy 
donors. MDM cells were pretreated with virus like particles containing Vpx (VLP+Vpx), 
control VLP without Vpx and infected with PERV-A/C for 48 h. Cells were collected and 
washed two times with PBS, after that RNA was isolated; cDNA synthesized and used for 
qPCR to quantify the relative mRNA induction of CXCL-10, IFN-β and ISG-54. In results 
presented in Fig.5.16, the result indicated that PERV-A/C infection induced CXCL-10 in 
MDM of one donor thousand fold and with other two donors to above hundred fold. 
Knockdown of SAMHD1 by the accessory protein Vpx didn`t change the CXCL-10 









































































Figure 5. 16 CXCL-10 is significantly induced by PERV-A/C infection in MDMs. MDMs were 
differentiated for 6 days from PBMCs by GM-CSF. Non infected cells were set to one. ΔΔCT method 
was used to calculate the fold difference. Mean values and SEM are shown. *P<0.05; **P<0.005; 
unpaired t-test. 
As shown in Figure 5.17, PERV-A/C infection failed to induce significant levels of IFN-β in 
MDM cells in contrast to treatment with poly I.C. IFN-β has been however slightly induced in 
MDM of one donor without reaching significant levels. 
As with the results obtained with IFN-β, the relative mRNA of ISG-54 was not significantly 
induced by PERV-A/C infection in MDM cells as well (Fig.5.18). From three donors just one 
donor appeared with slightly induced of ISG-54 response to PERV-A/C infection. Heat 
inactivated viruses served as a negative control, while poly I.C treatment served as a positive 
control. 
5.2.3 CXCL-10 induction is increased in monocytes by PERV-A/C infection 
To confirm the induction of CXCL-10 by PERV-A/C in other cells, monocytes were used. 
Monocytes were isolated from buffy coats of three healthy human donors and differentiated to 
monocytes. Monocytes were pretreated with VLP+Vpx or control VLPs without Vpx for 3h, 
after that, cells were infected with PERV-A/C. RNA was isolated 48h post infection and 
CXCL-10 mRNA was quantified by qPCR. As with MDDCs and MDM cells, PERV-A/C 
induced the production of CXCL-10 in monocyte cells (Fig.5.19). The addition of VLP with 
Vpx to the monocytes played no important role. Heat-inactivated PERV-A/C did not result in 












































































Figure 5. 17 IFN-β failed to be activated by PERV-A/C infection in MDMs. PERV-A/C was used 
as stimulator for IFN-β and poly I.C as a positive control. The IFN-β mRNA level was quantified by 
qPCR. Non infected cells were set to one and used as a calibrator for measurement of the fold 
difference. ΔΔCT method was used to calculate the fold difference for infected and non-infected cells 
to GAPDH. Mean values and SEM are shown. *P<0.05; **P<0.005; unpaired t-test.  
 
 
Figure 5. 18 PERV-A/C infection does not induce ISG-54 in MDMs. The cells were infected by 
PERV-A/C, transfected with poly I.C or not-infected at all. After RNA isolation, the ISG-54 relative 
mRNA was quantified by qPCR. Non infected cells were set to one and used the ΔΔCT method to 
calculate the fold difference to GAPDH. Mean values and SEM are shown. *P<0.05; **P<0.005; 












































































































































Figure 5. 19 In monocytes the induction of CXCL-10 to PERV-A/C infection was significant.  
Monocytes were differentiated from PBMCs by adherence. Cells were infected with a PERV-A/C 
recombinant virus after pretreatment with virus like particles containing Vpx (VLP+Vpx), control 
VLP or without pretreatment. The CXCL-10 mRNA was quantified by qPCR. Heat-inactivated PERV 
served as a negative control and the poly I.C transfection served as a positive control. The amounts of 
mRNA quantified in non-infected cells were set to one and used the ΔΔCT method to calculate the 
fold difference to GAPDH. Mean values and SEM are shown. *P<0.05; **P<0.005; n.s. not 
significant, unpaired t-test. 
5.2.4 A JAK inhibitor reduces the CXCL-10 inductions in MDM 
The previous results demonstrated a significant relationship between the CXCL-10 mRNA 
induction levels and the PERV-A/C infection. It is therefore necessary to identify the immune 
sensors and signaling pathways, which play a role in the CXCL-10 response in human 
immune primary cells infected by PERV-A/C. To investigate that, human primary MDM of 
six donors were pretreated with 1µM of different inhibitors (NF-B inhibitor; Parthenolide, 
JAK inhibitor; AT9283, TBK1 inhibitor; BX-795, and a TLR7/8 antagonist; R837) for one 
hour before infection with PERV-A/C. 48 h post infection, RNA was isolated; cDNA 
synthesis of CXCL-10 mRNA was quantified by qPCR. The results show that only the JAK 
inhibitor reduced the induction of CXCL-10 by PERV-A/C. The pretreatment with inhibitors 
of NF-B, TBK1 and TLR7/8 failed to reduce the CXCL-10 induction (Fig.5.20). The results 











































































Figure 5. 20 The JAK-STAT pathway is involved in the CXCL-10 response in MDMs to PERV-
A/C infection.  Cells were seeded and differentiated in 12-well plates. Before  infection by PERV-
A/C, cells were pretreatment with the indicated inhibitors (JAK (AT9283), TBK1 (BX-795), NF-κB 
(Parthenolide) and the TLR7/8 antagonist (R837) for 30 min. 48 h post infection, RNA was isolated 
and CXCL-10 mRNA quantified by qPCR. The results of non-infected cells were set to one and the 
ΔΔCT method was used to calculate the fold difference to GAPDH. Mean values and SEM are shown. 
*P<0.05; **P<0.005; n.s. not significant, unpaired t-test. 
5.2.5 CXCL-10 induction by PERV-A/C is also inhibited in MDDCs by the JAK-
inhibitor AT9283  
As above, MDDCs were pretreated with 1 µM of different inhibitors (NF-B inhibitor; 
Parthenolide, JAK inhibitor; AT9283, TBK1 inhibitor; BX-795, TLR7/8 antagonist; R837) 
for one hour before infection with PERV-A/C. RNA was isolated 48 h post infection and 
CXCL-10 was measured by qRT-PCR. The result in MDDCs provides further evidence that 
CXCL-10 induction is inhibited by the JAK inhibitor (AT9283). This was the case in all six 
donors tested. (Fig.5.21). In addition to the JAK inhibitor, the TBK1 inhibitors (BX-795) 
reduced the CXCL-10 activity in MDDCs as well, but about 10 times less effective than 
AT9283. Moreover, the NF-B inhibitor did slightly reduce the amount of CXCL-10 
induction as well. However, considerable donor dependence has been noticed (Fig.5.21). The 

















































































the type of inducers. The JAK-STAT pathway is the main way that PERV-A/C is using to 
induce CXCL-10 in human primary myeloid cells 
 
Figure 5. 21 Analysis of inhibitors of innate immune pathways for induction by PERV-A/C in 
MDDCs. Differentiated cells were pretreated with JAK (AT9283), TBK1 (BX-795), NF-κB 
(Parthenolide) inhibitors and the TLR7/8 antagonist (R837) for 30 min before infection with PERV-
A/C. The relative mRNA of CXCL-10 was quantified by qPCR 48 h post infection. The results of 
non-infected cells were set to one and the ΔΔCT method was used to calculate the fold difference to 





















































































6.  Discussion 
In human cells, retroviruses replication can be restricted by multiple barriers. Viral replication 
can either be limited due to missing cellular co-factors, which retroviruses take for efficient 
replication, or due to the presence of restriction factors such as APOBEC3G, Fv1, TRIM5α, 
tetherin and SAMHD1, which block viral replication at different steps of the life cycle [120, 
121]. Previous studies have investigated the potential of other well-described retroviral 
restriction factors to block PERV transmission from pigs to humans: various members of the 
human and porcine family of APOBEC3 cytidine deaminases potently block PERV 
replication in tissue, thereby reducing the risk of infection of human cells by PERV during 
xenotransplantation [220, 221]. Tetherin (or BST-2), which prevents retroviral budding, was 
also found to potently inhibit PERV replication in human cells [138]; in contrast, 
TRIM5alpha proteins from various species did not restrict PERV replication [222].  
The risk of PERV transmission to various human cells is high during xenotransplantation, 
because PERVs are integrated within the genome of all pigs and the ability of PERVs to 
infect human cells in vitro was confirmed. Therefore, it is important to investigate the role of 
human SAMHD1 in restricting the transmission of PERV from pig organs to human 
recipients during xenotransplantation. The sterile alpha motif domain and HD domain 
containing protein 1 (SAMHD1) is a restriction factor that potently blocks infection of a 
variety of human and nonhuman retroviruses independent of the origin of the viruses [144, 
223]. 
In addition, it is important to mention that the zoonotic potential of virus transmissions during 
xenotransplantation is not limited to PERV. Recent publications identified hepatitis E virus 
(HEV) and the porcine cytomegalovirus (PCMV) as potential risk factors for the transplant 
recipient [224, 225]. In transplant experiments where baboons received a heart from HEV 
positive donor pigs the virus was detected in the recipient as well [226]. For 
xenotransplantation to become a clinical routine, not only immunological and anatomical 




6.1 PERV-A/C life cycle is inhibited by SAMHD1 in human primary cells  
6.1.1 SAMHD1 restricts PERV-A/C in MDDCs by depleting cytoplasmic dNTPs 
In the present work, the antiviral activities of SAMHD1 to restrict PERV in MDDCs were 
investigated. The restriction function of SAMHD1 for HIV-1 and other retroviruses was 
assessed in MDDCs and other immune primary cells previously [223]. In general, the reverse 
transcription of most retroviruses requires a preexisting pool of dNTPs in the target cell. 
Therefore, nucleotide pool depletion by SAMHD1 could be a general mechanism to restrict 
the replication of different genera of retroviruses. The findings in this work confirm that 
SAMHD1 restricts the replication of PERV-A/C at the reverse transcription in MDDCs. This 
has been demonstrated in MDDCs of many donors (Fig.5.2). The delivery of Vpx by HIV-1-
VLPs into the MDDCs degrades SAMHD1 and the RNA genome of PERV-A/C can be 
reversed transcribed into cDNA. The results from Sunseri and coworkers also demonstrated 
that Vpx containing HIV-1 increase the HIV-1 infectivity nearly 100-fold on MDDCs [168]. 
In previous studies, it has been demonstrated that SAMHD1 can be restricted HIV-1 in 
MDDCs at the reverse transcriptase step, they found that SAMHD1 restricted infection by 
depleting intracellular deoxynucleosides triphosphates (dNTPs), reducing their concentrations 
to below those required for the synthesis of the viral DNA by reverse transcriptase [127, 143].  
Normally, to successfully replicate, retroviruses and some DNA viruses, which replicate 
through a DNA intermediate, they need access to an intracellular supply of dNTP. To 
understand if PERV-A/C is restricted by the low abundance of dNTPs in MDDC, I 
supplemented the cell culture with 1 mM dN for 30 min prior to infection with PERV and 
VLP lacking Vpx or with Vpx. The results show a similar increase of PERV reverse 
transcripts in MDDCs treated with 1 mM dN compared to the addition of Vpx-VLP, that 
means the capability of SAMHD1 was not sufficient to deplete the endogenous and 
exogenous deoxynucleotides (Fig. 5.4). A combination of dN supplementation and Vpx-VLP 
treatment results in a further enhancement either suggesting an additional restriction 
mechanism to dNTP pool depletion or resulting from the fact that SAMHD1 protein was not 
completely degraded by Vpx as seen by the western blot (Fig.5.4). In another study, the 
authors found that the treatment of cells with deoxynucleosides was less efficient to induced 
the reverse transcription than was treatment with Vpx-containing VLPs, perhaps because cells 
treated with deoxynucleosides continue to deplete the dNTPs by SAMHD1, while in cells 
exposed to Vpx-containing VLPs, SAMHD1 is degraded, which prevents depletion of dNTPs 
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[127]. The results from an additional previous study suggest that SAMHD1 can restrict 
retroviruses in the case of low cellular dNTP levels and it lacks its antiviral activity due to the 
high dNTP levels, like in Hela cells [227]. Moreover, recently, it was demonstrated that the 
imbalance of dNTP pools in macrophages can significantly inhibit cDNA synthesis by HIV-1 
reverse transcriptase and the increased dNTP bias induced the viral mutant rate by about 20–
30% per a single cycle infection [228]. 
6.1.2 The antiviral activity of SAMHD1 inhibits PERV-A/C in monocytes and MDMs 
Monocytes and macrophages are at the front line in the immune defense against external 
invasion by pathogens, providing the first virus-cell contact during infection. In addition, 
monocytes and macrophages are considered as partially resistant cells for HIV-1 and others 
virus’s infection. The restriction factors SAMHD1 can restrict the PERV-A/C reverse 
transcription in monocytes and in the absent of SAMHD1 PERV-A/C produced cDNA by 
reverse transcription (Fig.5.5). The same result was also found in MDM, SAMHD1 blocks the 
replication cycle for PERV-A/C by depleting the intercellular dNTP at reverse transcription 
(Fig.5.6). The restriction function of SAMHD1 for PERV-A/C in monocytes and MDMs in 
this study corresponds to those reported in similar studies [127, 143, 223] showing its 
antiviral activity for blocking HIV-1 replication cycles in the human primary cells. In 
agreement with this result, it was reported that monocytes and macrophages can resistant the 
lentivirus and gammaretrovirus infection under special circumstances [229, 230]. In another 
side, host restriction factor SAMHD1 inhibits human T-cell leukemia virus type 1 infection of 
monocytes by inducing cells apoptosis [163]. In another study it was found that the Vpx 
protein increases the cellular dNTP concentration by degrading SAMHD1 above the threshold 
values of HIV-1 reverse transcription in macrophages, which can induce the reverse 
transcription activity and virus infectivity in macrophages [231]. Also in MDM cells vaccinia 
virus replication in primary human monocyte-derived macrophages was enhanced by Vpx-
mediated degradation of SAMHD1 [150]. 
In (Fig.5.6) the shown result demonstrates that the AZT treatment (PERV+VLP-no 
Vpx+AZT) lowered significantly the amount of PERV-A/C cDNA compared with untreated 
(PERV+VLP-noVpx) in MDM cells, that means SAMHD1 can only partial inhibit the PERV-
A/C reverse transcription and PERV-A/C can produce cDNA in the present of SAMHD1. The 
previous result was in agreement with our work, that HIV-1 can partially infect macrophages 
in the face of SAMHD1 restriction [232, 233]. In contrast with HIV-2 and SIV, which are 
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incapable to infect macrophages except if SAMHD1 is eliminated by the accessory protein 
Vpx and the intracellular dNTP concentrations are increased to levels appropriate for viral 
cDNA production [233]. It was also demonstrated that human cytomegalovirus reduces the 
steady-state SAMHD1 expression levels and increases SAMHD1 phosphorylation using the 
viral kinase pUL97 in macrophages [234]. The same results were obtained with other tissue 
macrophages, which HIV-1 has the ability to infect. These cells are used as a viral reservoir, 
like microglia in CNS and osteoclast in bone [235-237]. In a recent study, the authors 
demonstrated that the antiviral activity of SAMHD1 in MDM is sex-dependent; SAMHD1 
exists in a hyper phosphorylated and less active state in male-derived macrophages then in 
female-derived macrophages. In addition, the SAMHD1 phosphorylation by CDK1, presented 
lower levels of expression in female-derived macrophages in all tested donors [238]. Jauregui 
et al. found the DNA damage in MDMs by neocarzinostatin, blocking HIV-1 infection by 
decrease of the phosphorylated SAMHD1 and activating its antiviral activity [239]. In 
contrast to many studies, it was reported in one other study that the RNase activity of 
SAMHD1 is responsible for blocking HIV-1 infection by directly degrading the HIV-1 RNA 
in monocytes and MDM [240]. 
6.1.3 The replication cycle of PERV-A/C in THP-1 cells can be restricted by SAMHD1 
at reverse transcriptase 
In the last experiment, SAMHD1 was knocking down by Vpx in MDDCs to find out its 
antiviral activity. To further verify the restriction function of SAMHD1 for PERV-A/C, THP-
1 cells with a stable CRISPR/Cas9 knock-out of SAMHD1 were used. THP-1 cells were 
differentiated with 30 ng ml-1 PMA 72 h prior to infection. The reverse transcription products 
of PERV-A/C in THP-1 cells with a knock-out SAMHD1 status were 10 fold more 
susceptible to infection compared with control cells expressing SAMHD1. This indicates that 
SAMHD1 is able to counteract PERV-A/C infection in non-dividing THP-1 (Fig.5.7). This is 
consistent with the findings in previous studies which did also use THP-1 lacking SAMHD1 
and infected them with HIV-1. They found that HIV-1 infectivity is higher in the absence of 
SAMHD1 in differentiated or not-differentiated THP-1 cells [241, 242]. It has been also 
reported that SAMHD1 can be restricted by HCMV in THP-1 cells by comparing the levels of 
infectious HCMV particles product in Knock-out THP-1 cells with HCMV-infected control 
cells [234]. In another study, authors used RNA downregulation by shControl and 
shSAMHD1 vectors to reduce SMAHD1 expression in THP-1 cells to determine whether the 
restriction to FIV, EIAV and SIV infection was also caused by SAMHD1 in differentiated 
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cells. They found that the SAMHD1 knock-down relieved the block to infection for all viruses 
and that Vpx containing VLP had no further effect [223]. In addition, it was demonstrated that 
SAMHD1 blocks replication of the HSV-1 DNA genome in differentiated macrophage cell 
lines. Knockdown of SAMHD1 in THP-1 cells enhanced HSV-1 replication [149].  
6.1.4 SAMHD1 restriction of PERV-A/C in CD4+ T-cells 
I addition to myeloid immune cells, SAMHD1 is also expressed to high levels in CD4+ T- 
lymphocytes, which are consider the main targets of HIV-1, also important for the virus 
reservoir and viral latency. The antiviral activity of SAMHD1 against PERV-A/C in CD4+ T-
cells was different in activated and resting-CD4+ T-cells. The PERV-A/C cDNA product from 
reverse transcription in activated CD4+ T-cells was higher with around 10 fold compared with 
resting CD4+ T-cells. This result indicated that SAMHD1 restricted PERV replication cycle in 
resting but not activated CD4+ T-cells (Fig.5.11). The report from a previous study is in 
agreement with this finding, that the deoxynucleoside triphosphate triphosphohydrolase 
SAMHD1 prevents reverse transcription of HIV-1 RNA in resting CD4+ T-cells [147]. The 
SAMHD1 role in HIV-1 latency remains unknown; therefore in one study the authors 
demonstrated that SAMHD1 suppressed not only HIV-1 gene expression but also reactivation 
of viral latency in primary CD4+ T-cells [243]. 
In (Fig.5.9) the VLP+Vpx failed to increase PERV RT products significantly in resting CD4+ 
T-cells; however we were unable to reduce SAMHD1 levels to sufficient amounts using this 
approach (Fig.5.9, lower). Baldauf et al. demonstrated that virion-packaged Vpx proteins 
from a second SIV lineage, SIV of red-capped mangabeys or mandrills (SIVrcm/mnd-2), 
enhanced HIV infection in resting CD4+ T-cells without any effect on SAMHD1 degradation, 
dNTP pool elevation, or changes in SAMHD1 phosphorylation [244]. It has been reported in 
a different study that SAMHD1 in resting CD4+ T-cells was much less efficiently degraded by 
VPX compared with primary monocytes. In one study they pretreated resting CD4+ T-cells 
with VLP-Vpx before they infected cells with HIV-1, after 96 h an average of 14% of resting 
CD4+ T lymphocytes were expressed HIV-1 EGFP [145]. The divergences in Vpx-mediated 
loss of SAMHD1 in resting CD4+ T-cells and other human primary cells might result from 
differences in nuclear/ cytoplasmic exchange [245] and the nuclear Vpx alleles were only 
capable of diminishing a nuclearly localized SAMHD1 [246]. 
It was demonstrated that SAMHD1 lost its antiviral function in cycling cells by 
phosphorylation on residue T592 without affecting its ability to decrease cellular dNTP levels 
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[247]. In agreement with previous results, in Fig.5.10 the results show no role of SAMHD1 
antiviral activity to restrict PERV-A/C in activated CD4+ T-cells and the amounts of 
SAMHD1 expression were similar in Fig.5.10. The dNTP triphosphohydrolase activity of 
SAMHD1 continues during phosphorylation at T592 and achieves an important regulatory 
role to maintain dNTP pool balance for proper DNA replication [248]. In contrast, the result 
of another study show that SAMHD1 restricts the replication of Line1 and other endogenous 
retroelements in cycling cells, that means the function of SAMHD1 in antiviral activity and 
controlling autoimmunity might not only depend on the dNTP hydrolase activity [249]. 
The addition of 1 mM exogenous deoxynucleosides to the resting CD4+ T-cells increased the 
PERV-A/C cDNA products significantly (Fig.5.12a). A similar result was achieved with 
MDDCs (Fig.5.4) that explain the addition of deoxynucleosides overcome the SAMHD1 
restrictions to PERV-A/C infection in resting CD4+ T-cells. On the other hand, the addition of 
deoxynucleosides to the activated CD4+ T-cells failed to induce the RT product of PERV-A/C 
(Fig.5.12.b). Previously published data indicate that the addition of deoxynucleosides 
promoted HIV-1 integration and 2LTR formation in resting CD4+ T-cells, but not in activated 
CD4+ T-cells [250]. In another study the authors reported that dNs enhanced HIV-1 infectivity 
in resting CD4+ T-cells in the absence of Vpx, while not affecting the activation status of the 
cells [147].  
In conclusion, this study we provide strong evidence that SAMHD1 potently blocks PERV 
reverse transcription in MDDCs, primary human monocytes and MDMs as well as in the 
differentiated THP-1 cells line. The block could be relieved by treatment with Vpx or by 
addition of 1 mM deoxynucleosides during infection, both interventions are well known to 
overcome the enzymatic activity of SAMHD1. Unlike activated CD4+ T-cells, resting CD4+ 
T-cells that express SAMHD1 did not support PERV RT and this block could also be 
alleviated through addition of 1 mM dN. The SAMHD1- mediated PERV-A/C restriction in 
non-cycling myeloid cells and resting CD4+ T-cells may help develop new therapeutic 
approaches against PERV-A/C infection by a combination with other available restriction 
factors and anti-PERV-A/C.  
6.2  The interferon response to PERV-A/C infection 
Innate immune responses are the first line of defense against invading pathogens. Nucleic 
acids of many viruses are major structures detected by the innate immune system. Cytosolic 
DNA sensors activate different signaling pathways leading to activation of transcription 
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factors such as the IFN regulatory factor 3 (IRF3) or nuclear factor kappa B (NF-κB), which 
are responsible for the production of type one IFN. The IFNs bind to the IFN-receptor and 
induce the JAK/STAT pathway that lead to enhanced expression of IFN-stimulated genes, 
which play an important role in the immune defense against viral infection.  
In xenotransplantation, it is necessary to demonstrate the interferon response of human 
immune primary cells for PERV-A/C infection in order to understand the immune response 
after xenograft reception and to avoid the immune rejection that can be caused by this 
response.  
6.2.1 PERV-A/C infection induces IP-10 in human primary cells 
The results provided within this thesis indicate that CXCL-10 (IP-10) was the most 
significantly related cytokine in response to PERV-A/C infection in MDDCs, MDMs and 
monocytes (Fig.5.12, 16, 19). CXCL-10 has been shown to induce chemotaxis in different 
cell types of the immune system by binding to the CXCR3 receptor [251]. The CXCL-10 
expression is inducing in several cells signaling pathways, therefore, the CXCL-10-response 
is high in most virus infections, inflammation and cancer (Fig.6.1) [252].  
 
Figure 6. 1 Schematic model of the signaling pathways that play a role in the induction of 
CXCL-10 in human macrophages, microglia, epithelial and cancer cells [252]. 
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In agreement with our results, one other study has demonstrated that the CXCL-10 mRNA is 
highly expressed in HIV-1 infected monocytes and MDDCs and the increase level is 
associated with HIV-1 viral load [253]. Similar to our finding that PERV-A/C potently 
induces CXCL-10 expression in immune cells, others have reported that IP‐ 10 is induced at 
higher levels with the acute phase of Zika virus infection in monocyte of pregnant women 
[254]. The results in this work are in agreement with a recently report by Loevenich et al. 
showing that human metapneumovirus (HMPV) efficiently stimulated CXCL-10 mRNA in 
MDMs and MDDCs [255]. This is in line with other previous studies showing that herpes 
simplex virus type 1 (HSV-1) infection activates CXCL-10 gene expression in these cell types 
[256]. There is a controversy about the role of CXCL-10 in virus infection, some reports show 
that CXCL-10 can dominate and drive immune protective response functions against virus 
infection, like with coronavirus and herpes simplex virus type2 (HSV-2) infection [257, 258]. 
In contrast, others demonstrated that CXCL-10 enhances HIV-1 infection by activating virus 
replication in macrophages and lymphocytes [258-260]. It seems that the host immune status 
and genetic background influences the function of CXCL-10 and decides whether it either 
protects or promotes infection [261]. Moreover, in one study, it was reported that CXCL-10 
acted as an antitumor agent. It stimulates damage in recognized tumor blood vessels and 
causes tissue necrosis in human Burkitt lymphomas in the mouse model [262].  
The IFN- β was a second important innate immune response investigated in this work, which 
is a cytokine and belongs to a type I interferon produced by immune cells in response to viral 
infection and other pathogens. In contrast to CXCL-10, the induction of IFN-β in human 
primary cells MDMs and MDDCs to PERV-A/C infection was not significant compared with 
uninfected cells and the positive control poly I.C (fig.5.14, 17). Many viruses have developed 
mechanisms to avoid the IFN response and to facilitate their infection, like HIV-1, which 
manipulates the induction of IFN response in macrophage and dendritic cells through 
inhibition of TBK1 autophosphorylation by its accessory proteins Vpr and Vif [263]. These 
findings completely agreed with results documented in another study showing that single-
round pseudotyped HIV-1-based reporter viruses did not activate sensing pathways and failed 
to induce innate immune responses in cell lines and immune cells that were otherwise 
responsive to external nucleic acids [264]. On the other hand, in a previous report it has been 
also observed that herpes simplex virus type 2, Sendai and HIV-2 viruses significantly 
induced IFNβ [263, 265]. In addition, it has been reported that multiple-round replication of 
HIV-1 can induce the innate immune responses leading to increased levels of IFN-β secretion 
and sensing in MDDCs before and after virus integration [266, 267]. 
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Interferon stimulated genes (ISGs) induced predominantly by the activation of JAK/STAT 
pathway after IFNs bind receptors on surrounding cells. ISGs serve to stand an antiviral state 
within a host cell, the specific antiviral function of many ISGs has been described and the 
function of others ISGs remains to be determined. To check the response of ISG-54 to PERV-
A/C infection, MDDCs and MDMs were used. The results show no marked response for ISG-
54 to PERV-A/C in macrophage and dendritic cells (Fig.5.15, 18). Similar results were 
reported in previous studies that HIV-1 cannot be recognized in that way that leads to a 
stimulation of these ISGs by the innate immune response [263, 264]. The results of Nasr et al. 
demonstrated that infection of human MDMs with HIV-1 induced a number of interferon 
stimulated genes without stimulation of any type of interferons; this inhibition was mediated 
by HIV-1 inhibition of IRF3 translocation to the nucleus [268]. In addition, the authors found 
in another study that Vif and Vpr of HIV-1 degraded IRF3 in MDDCs and prevent the 
antiviral response during the very early phase of replication [269]. On the other hand, it has 
been found that several ISGs upregulated during HCMV infection independently of type one 
IFN-initiated JAK-STAT signaling, but were dependent on the intact IRF3 signaling pathway 
[270]. 
In conclusion, our findings demonstrate for the first time that MDMs, MDDCs and monocytes 
produce significant amounts of CXCL-10 in response to PERV-A/C infection. It has been 
reported in several studies that the induction of CXCL-10 can be based on different cell 
signaling pathways; therefore usually the CXCL-10 response is high in many virus and 
bacterial infections. However, MDDC, MDM cells do not mount efficient IFN-β and ISG-54 
response to PERV-A/C infection, mainly due to restriction of virus reverse transcription, 
which prevents production of viral cDNA [271] and limits its detection through the cGAS-
STING pathway. Additionally, the lack of IFN-β and ISG-54 activation by PERV-A/C in 
these cells might be not due to a lack of sensing pathway components but rather due to the 
virus not stimulating those pathways.  
6.2.2 The JAK-STAT pathway is involved in the CXCL-10 response that follows an 
infection of human myeloid cells by PERV-A/C  
After we confirmed that CXCL-10 can be induce by PERV-A/C infection, the following aim 
was to identify the sensors and signaling pathways, which play a role in the CXCL-10 
response in human primary myeloid cells infected by PERV-A/C. Human immune primary 
cells were treated with different cell signaling inhibitors. The results show that the JAK-
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inhibitor (AT9283) reduced the CXCL-10 induction in infected cells but the other inhibitors 
TBK1 (BX-795), NF-κB (Parthenolide) and a TLR7/8 antagonist failed to reduce the 
induction of CXCL-10 in MDM cells (Fig.5.20). The response is sensitive to the JAK-
inhibitor indicating that the JAK-STAT pathway is involved in the response. In MDDCs, the 
JAK (AT9283) and TBK1 (BX-795) inhibitors lowered the amount of CXCL-10 activation 
compared with untreated cells (Fig.5.21). The JAK/STAT signaling pathway is very 
important in the innate immune response for transmitting extracellular chemical signals like 
IFN binding to the nucleus and thereby inducing the transcription of IFN-stimulated genes. 
The results of this work are in agreement with previous work from Sakar et al, showing that 
blocking of the JAK-STAT pathway by a JAK inhibitor almost completely inhibited CXCL-
10 production by respiratory syncytial virus infection, that means that the JAK-STAT 
pathway is involved in CXCL-10 induction, while the NF-κB pathway appeared to be not or 
only slightly involved [272]. In another study, it was reported that human rhinovirus induced 
CXCL-10 activation in monocytes through JAK/STAT pathway activity [273]. The cofactor 
of aminoacyl-tRNA synthetase p43 induces both the mRNA and protein expression of CXCL-
10 through the JAK-STAT signaling pathway in HMEC-1 cells to inhibit angiogenesis and 
suppress tumor growth [274]. The production and regulation of CXCL-10 depend on the type 
of inductions and the target cells.  Rabies virus (RV) activate CXCL-10 expression in 
macrophages by stimulation of extracellular signal-regulated kinases 1 and 2 (ERK1/2) [275], 
while in microglia in the central nervous system the induction of CXCL-10 was achieved 
through the activation of p38 and NF-kB pathways [276]. In contrast to the previously 
mentioned study, the authors found that the induction of CXCL-10 promotes cell proliferation 
and contributes to the development of tumors by the Raf, PI3K, p38/MAPK, JNK/MAPK and 
NF-κB signaling [277]. On the other hand, the abrogation of CXCL-10 expression in target 
cells by inhibiting the JAK/STAT1 signaling pathway might be used as anti-inflammatory 
effects through reduction of chemokine CXCL10 activation, like in murine macrophage-like 
cells [278].  
In conclusion, the expression of CXCL-10 can be induced with different cell signaling 
pathways depending on the type of inducers and the target cells. For PERV-A/C, the JAK-
STAT pathway is the main way that PERV-A/C is using to induce CXCL-10 in human 
primary myeloid cells. Understanding the mechanism of CXCL10 production and regulation 
is very important. It might be supportive in the treatment of human diseases, because CXCL-
10 is activated and upregulated in different types of infections and diseases.  
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9.     Appendix 
9.1 Abbreviations:  
AIDS:                  acquired immune deficiency syndrome 
APOBEC3:          apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3 
AZT:                    azidothymidine 
BST-2:                 bone marrow stromal cell antigen 
CDK1:                 cyclin-dependent kinase 1  
cGAS:                  cyclic GMP–AMP synthase  
CXCL-10:            C-X-C motif chemokine 10 
CRISPR/Cas9:     clustered regularly interspaced short palindromic repeats 
CT:                      cycle threshold 
DNA:                   deoxyribo nucleic acid 
dN:                      deoxyneucleoside 
EBV:                   epstein barr virus 
Env:                     envelope   
ERV:                   endogenous retroviruses 
FAM:                   fluorescein amidite 
FITC:                   fluorescein isothiocyanate 
Fw:                      forward 
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Gag:                     group-specific  antigen 
GAPDH:              glyceraldehyde 3- phosphate dehydrogenase 
GM-CSF:             granulocyte macrophage colony stimulating factor 
GMP-AMP:         guanosine monophosphate-adenosine monophosphate 
HERVs:                human endogenous retroviruses  
HEX:                    hexachloro-fluorescein 
HCMV:                human cytomegalovirus 
HHV-8:                human herpes virus 8  
HEK-293:            human embryonic kidney cell-293 
HIV:                    human immunodeficiency virus 
HSV-1:                herpes simplex virus-1 
HTLV:                 human T-cell lymphotropic virus 
ICTV:                  international committee on taxonomy of viruses  
IFN:                     interferon  
IFI16:                   interferon-γ inducible protein-16 
IRF:                     interferon regulator factor 
JAK-STAT:         Janus kinases- signal transducer and activator of transcription proteins 
IP-10:                   interferon gamma-induced protein-10 
IRDye:                 infrared dye 
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ISG:                     interferon stimulated gene 
IU:                       international unit 
KO:                      knockout 
LTR:                    long terminal repeat  
MAB:                   monoclonal antibody 
MDM:                  monocyte derived macrophage 
MDDC:                monocyte derived dendritic cell 
MMTV:                mouse mammary tumor virus  
NF-κB:                 nuclear factor 'kappa-light-chain-enhancer' of activated B-cells 
qPCR:                  quantitative polymerase chain reaction 
PAMP:                 pathogen-associated molecular pattern 
PBMC:                 peripheral blood mononuclear cell 
PBS:                     primer-binding site  
PERV:                  porcine endogenous retrovirus 
PK15:                   porcine kidney-15 
Pol:                       polymerase   
PRR                      pattern recognition receptor 
Rev:                      reverse 
RLR:                     RIG-I-like receptors  
93 
 
RNA:                    ribonucleic acid 
ROX:                    6-Carboxyl-X-Rhodamine (dye) 
RSV:                     rous sarcoma virus  
RT:                        reverse transcriptase 
SAMHD1:            sterile alpha motif domain and HD domain containing protein 1 
SIV:                      simian immunodeficiency virus 
SIVcpz:                 SIV of chimpanzee 
SIVsm:                  SIV of sooty mangabey 
STLV:                   simian T-cell leukemia virus 
TBK1:                   TANK binding kinase 1 
TCID50:                50% tissue culture infective dose 
TLR7/8:                 toll-like receptor 7/8 
TRIM5:                 tripartite motif-containing 5 alpha 
VLP:                     virus like particles 
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